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Abstract   
 
Background and Aim of this Work  
Acute myeloid leukaemia (AML) is a fast proliferating haematologic cancer, causing 
death usually within weeks if untreated. Even though many patients achieve complete 
remission after initiating chemotherapy, relapse occurs frequently and is a main cause 
of therapy failure. The lysine-protein methyltransferase EZH2 is part of a repressive 
protein complex, mediating the tri-methylation on histone H3 lysine K27 and it has 
been reported to be overexpressed in many different types of cancer. Especially loss of 
function (LOF) mutations are prevalent in myeloid neoplasms and loss of EZH2 has 
been suggested to induce chemotherapy resistance in AML cell line models. Clinical 
observations and functional data in relapsed AML have shown that loss of EZH2 
expression might contribute to drug resistance in AML.  In this study we focussed on 
the functional characterization of EZH2 mutations using different biological 
approaches applying patient material, patient-derived xenograft (PDX) models (in vitro 
and in vivo), human AML cell lines and clinical data.  
Results and Conclusion 
By analysing protein and mRNA expression levels, we found a decrease in EZH2 
expression in 23-50% of AML patients. Additionally, low expression of EZH2 is 
correlated with a poor overall survival (OS) and a poor relapse free survival (RFS) 
interval. We found that EZH2 mutations, detected in AML patients, are loss of function 
(LOF) mutations and that protein loss of EZH2 induces resistance against cytarabine 
(AraC) in 293T cells and the myeloid cell line K652. Re-expression of EZH2-WT, but not 
of a LOF mutation is able to rescue drug sensitivity in K562 cells. Additionally, 
functional loss of EZH2 is associated with a drug resistant phenotype in a patient-
derived xenograft (PDX) model, both in vitro and in vivo. In summary, we show that 
functional inactivation of EZH2 promotes chemotherapeutic resistance in AML in vivo 
and in vitro and is involved in clonal evolution and disease progression, highlighting its 
clinical relevance. Our data also indicate, that treatment with EZH2 inhibitors, which 
are currently applied in clinical trials might drive resistance mechanisms in a subset of 
AML patients.   
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Zusammenfassung 
 
Hintergrund und Ziel der Arbeit  
Die akute myeloische Leukämie (AML) ist eine maligne hämatologische Erkrankung, 
die unbehandelt zum Tod führt. Obwohl die meisten Patienten innerhalb der initialen 
Therapie eine Remission erreichen, treten häufig Rezidive auf, welche die 
Hauptursache für ein finales Therapieversagen sind. EZH2 ist eine Lysin-Protein 
Methyltransferase und Teil eines repressiven Protein-Komplexes, welcher die Tri-
Methylierung von Histon3 Lysin27 (H3K27) vermittelt. Überexpression von EZH2 tritt 
in verschiedenen Tumorarten auf. In myeloischen Neoplasien werden im Speziellen 
Mutationen gefunden, welche zu einem Funktionsverlust führen. Klinische 
Beobachtungen deuten darauf hin, dass der Verlust von EZH2 einen Betrag zum 
Therapieversagen in der AML leisten könnte. Innerhalb dieser Arbeit wird daher die 
funktionale Charakterisierung von EZH2 unter Hilfenahme von Modellen wie humanen 
Zell-Linien, Patientenproben und patient-derived xenograft-(PDX)Zellen (in vitro und 
in vivo), thematisiert.   
Ergebnisse und Fazit 
Es konnte gezeigt werden, dass EZH2 mRNA- und Proteinexpressionslevel in 23-50% 
aller untersuchten AML Patienten zwischen Diagnose und Rezidiv verringert waren. 
Zusätzlich wurde gezeigt, dass eine niedrige Expression mit einem schlechten 
Überleben der Individuen mit AML korreliert. Es wurde gezeigt, dass mit Mutationen, 
welche in Patienten auftreten, ein Funktionsverlust einhergeht und dass der Verlust 
von EZH2 in 2 verschiedenen Zelllinien zu einer erhöhten Resistenz gegenüber dem 
Chemotherapeutikum Cytarabine (AraC) führt. Re-Expression des wildtyp Enzyms 
konnte dabei den resistenten Phänotyp wieder gänzlich aufheben, während eine LOF 
Mutante dazu nicht in der Lage war. Zusätzlich wurde in einem patient-derived 
xenograft (PDX) Modell gezeigt, dass eine LOF Mutante von EZH2 in vivo und in vitro 
resistenz-assoziiert ist. Zusammenfassend konnte in dieser Arbeit gezeigt werden, 
dass ein Funktionsverlust der Methyltransferase EZH2 die Chemotherapie-Resistenz 
in Patienten mit AML fördert und dass EZH2 in die klonale Evolution und 
Krankheitsprogression involviert ist. Die Daten deuten außerdem darauf hin, dass 
EZH2 Inhibitoren, welche derzeit in klinischen Studien getestet werden, Resistenz-
Mechanismen in bestimmten Subgruppen von AML Patienten fördern könnte.
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1. Introduction  
According to a 2018 World Health Organization (WHO) statement, cancer is the second 
most common cause of death worldwide, accountable for approximately 9.6 million 
deaths in that year1. Internationally, mortality is due to cancer in about one in six cases. 
Hence, the impact of cancer is significant and increasing worldwide. Haematological 
malignancies are widespread, being the fourth most frequently occurring cancer in 
economically developed areas of the world2–5. WHO has classified more than 60 
haematological cancer subtypes. These differ substantially in clinical presentation and 
treatment requirements6. 
 
1.1. Acute Myeloid Leukaemia 
1.1.1. Pathogenesis and Treatment 
Leukaemias are malignant disorders of the haematopoietic system causing an increased 
amount of non-functional progenitor leucocytes. Clinically and pathologically, leukaemias 
can be divided into several groups, including chronic leukaemias, which are slow-growing 
or acute leukaemias, which are fast-growing and characterized by rapid disease 
progression.  Both chronic and acute leukaemias are divided into two subgroups whereas 
the origin of malignant cell type determines whether they are termed myeloid or 
lymphatic.  Acute myeloid leukaemia (AML) is the most frequent acute leukaemia in 
adults, responsible for approximately 80% of cases7,8. AML is a highly heterogeneous 
disease, typified by the clonal expansion of aberrant, undifferentiated myeloid precursor 
cells9. This results in alterations of the haematopoietic system, including normal 
haematopoietic differentiation. As a consequence, an immense increase of immature 
myeloid cells in the bone marrow and the peripheral blood emerges. These so-called 
“blasts” are able to proliferate, but unable to differentiate into mature haematopoietic 
cells such as neutrophils or monocytes9. As a consequence, the absence of functional cells 
causes bone marrow failure, which is accompanied by clinical symptoms associated with 
to anaemia, thrombyocytopenia and granulocytopenia10. Left untreated, AML leads to 
death within a few weeks to months11. Even though many patients with AML respond to 
induction chemotherapy, relapse is very common and exemplifies the most important 
cause of therapy failure12,13. Albeit several new therapeutic strategies have been proposed 
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within the last years (including alternative anthracycline treatment, alternative cytotoxic 
agents and high-dose cytarabine induction therapy14–16), treatment with cytarabine 
(AraC) and daunorubicin (DNR) stays the standard care for AML patients17. The usual 
induction treatment for younger adults is composed of the “3+7” regimen which includes 
DNR (60mg/m2 intravenously for 3d) and standard-dose AraC (100mg/m2 administered 
via continuous infusion over 7d). This therapy ends in remission rates of 65% and 75% 
in patients aged 18–60 years18. Prognosis for older patients is much worse due to  death 
rates and resistance during therapy13,19. Complete remission (CR), which is defined as a 
bone marrow with less than 5% blasts, neutrophil count greater than 1000/µl and a 
platelet count greater than 100.000/µl is the only therapy response that leads to cure20. 
In an elongated treatment phase, the goal is to prolong CR status in order to achieve 
complete cure. When a patient reached CR for more than three years, the probability of 
relapse decreases to less than 10%21.  
 
1.1.2. Classification and Incidence 
Two main systems have been introduced to classify AML subtypes. The “French-
American-British” (FAB) classification and the more recent “World Health Organization” 
(WHO) classification. In the 1970s, a group of international experts divided AML into 
subtypes, M0 through M7. This classification system is founded on morphology and cyto-
chemistry22. AML classification was modernized in 2002 when WHO proposed a new 
taxonomy considering morphology, genetics and clinical parameters. Subsequently, the 
initial classification23  has been updated twice, most recently in 201624,25.  In 2014 the 
“Surveillance of Rare Cancers in Europe (RARECARE) project” aimed to summarize 
epidemiology of myeloid malignancies in Europe.  The overall annual incidence of myeloid 
malignancies was 8.6 per 100,000 wherein AML and myeloproliferative neoplasm (MPN) 
were detected most frequently, with incidence rates of 3.7 and 3.1 per 100,000 year 
respectively, slightly higher in males than in females. The 5-year relative overall survival 
for AML is 19% and incidence grows with increasing age26.  
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1.2. Clonal Evolution and Resistance in AML Relapse 
 
The ability of cancers to evolve and adapt is one of the major challenges when treating 
tumour patients in general.  Co-existence of multiple, heterogeneous subclones forming 
the tumour tissue provides the foundation of a dynamic evolutionary process. 
Consequently, the landscape of tumour tissue is always re-shaping during disease 
progression. Evidence supports the theory, that cancer clones are selected in an 
evolutional manner, relying on the simplest Darwinian evolution model27. Clones that 
persist post-chemotherapy are a serious challenge for the pharmacological treatment of 
AML patients as it was previously discussed a lot13,19,28. Clonal heterogeneity of AML 
therefore forms the basis of clonal evolution during disease progression and hypothetical 
explanations for treatment resistance. It is commonly accepted, that most cases of AML 
develop from a single pre-malignant transformed haematopoietic progenitor cell termed 
“leukemic stem cell” (LSC), which has specific characteristics, e.g., cytotoxic resistance 
properties27. Based on this concept many patients have residual AML within CR which is 
called “minimal residual disease” (MRD29). MRD is characterized by a small number of 
resistant cell clones that persist during treatment. One of the most explored mechanisms 
in treatment resistance is the deregulation of the drug efflux transmembrane ATPase P-
glycoprotein (P-gp; which is encoded by the MDR1 gene) which was investigated decades 
ago30. Detection of residual clones in CR might improve clinical outcome for patients 
where relapse is very likely since it has been recently shown, that approximately 75% of 
all patients already have pre-leukemic mutations in the peripheral blood, even 7 to 10 
years before AML is diagnosed31. Fast progression in the development of highly sensitive 
diagnostic tools, such as gene- and microRNA-expression, genome-wide single nucleotide 
polymorphism-based (SNP) mapping arrays  or next-generation sequencing (NGS) 
techniques offer more and more insight into the functional genomics of cancer and is 
encouraging for achieving a better understanding of the evolution of AML development. 
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Figure 1: Hypothetical development of AML showing clonal fractions at AML diagnosis and relapse. 
In the first model, cytotoxic treatment induces mutagenesis (a). In the second model, one resistant clone 
arises from the tumour mass after chemotherapeutic treatment (b). In the third model, resistance of clones 
does not differ and the cleared niche after therapy is populated within a dynamic evolutionary pattern (c). 
Eradication of all malignant AML clones leads to cure (d) in the fourth model (adapted from Landau et. al27).  
 
One question surrounding the difficult treatment of relapsed AML patients is how 
resistance develops during disease course. One major reason for resistance development 
is treatment with cytotoxic drugs. Several hypothetical possibilities can lead to resistance 
during chemotherapeutic treatment, founded on the model of clonal evolution of cancer 
cells27 (Figure 1). It is accepted that exposure to a certain chemotherapeutic drug can lead 
to the development of resistant clones. Whereas treatment with cytotoxic agents such as 
AraC minimizes the cell number in remission, therapy associated mutations arise during 
treatment and resistant clones offer the basis for clonal expansion in AML relapse 
(chemotherapy induced mutagenesis). In another scenario, resistant clones exist from the 
beginning of AML induction and these persist during chemotherapy, due to specific 
resistant characteristics. These clones survive treatment and re-expand after therapy is 
completed (selection of a resistance accelerating mutation). In a third model, the 
outgrowth of relapse associated cells is not founded by a single clone, but different cell 
clones repopulate the cleared niche, which has been created by cytotoxic clearing. In a 
dynamic pattern, which is influenced by evolutional selection pressure (competitive 
selection after cytotoxic clearing) repopulation takes place.  In the last scenario, AML can 
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be completely cured through the eradication of all malignant clones by chemotherapeutic 
treatment. 
 
1.3. Genetic and Epigenetic Factors with Prognostic Impact in AML 
1.3.1. Molecular Markers in AML 
 
In 2010, international leukaemia experts comprising the “European leukaemia Net” (ELN) 
published recommendations for diagnosis, prognosis and treatment of AML patients. 
These guidelines consider the prognostic value of  cytogenetic and molecular 
abnormalities32. The newest ELN recommendation33 classifies AML into the three 
prognostic risk categories: favourable, intermediate, and adverse. Even though functional 
consequences of many recurrent genetic alterations are not yet completely defined, 
mutations have become useful molecular markers for diagnosis and prognosis and are 
used routinely in the clinics33. The most recurrent mutations that appear in 
cytogenetically normal (CN)-AML patients are the fms-like tyrosine kinase FLT3 (39%), 
nucleophosmin NMP1 (33%) and the DNA methyltransferase DNMT3A (31%)34. Yet, 
several other mutations can be observed to originate from kinases, which are involved in 
cellular signalling processes to diverse transcription factors. Moreover, the combination 
of different mutations or rearrangements has an immense effect on patient outcomes. For 
example patients harbouring FLT3-ITD alongside NPM-1 wildtype alleles have a much 
poorer prognosis than patients with FLT3-ITD and mutated NPM-133.  
 
Figure 2: Histogram illustrating the spectrum of driver mutations detected in AML patients 
according to specific classification groups. Data obtained from Metzeler et al., 201634.  
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In a cohort of 664 patients Metzeler et al.34 presented the spectrum of driver mutations 
in AML patients aged 18-86 years (Figure 2), summarized in specific functional groups, 
including chromatin modifiers. Mutations in genes which are involved in the regulation of 
epigenetics have been described frequently in the past decades35–37 emphasizing the high 
importance of epigenetic regulation in the development and progression of cancer. 
 
1.3.2. Epigenetics and AML  
 
The term epigenetics refers to a heritable class of dynamic changes of chromatin 
structures and gene transcription, without altering the actual DNA sequence. Modification 
of chromatin structures which changes interaction between DNA and histones, are 
important physiological processes38. For example, these modifications permit 
transcriptional up- and downregulation of specific target genes, DNA repair, or 
replication. This includes DNA methylation, histone modifications, changes in nucleosome 
modelling, histone variants and non-coding RNAs39,40 which indirectly affect gene 
transcription38,41. Epigenetic regulators can be broadly classified into “writers” (including 
methyltransferases or acetyltransferases), “erasers” (including demethylases and 
deacetylases) and “readers” (recognition enzymes, e.g. PHD- and bromodomain-
containing proteins)42.  
 
Approximately 70% de novo AML patients show mutations in epigenetic modifiers that 
are involved in the methylation of  DNA or histone modelling43. Methylation of DNA is 
associated with the transcriptional repression by formation of heterochromatin which is 
achieved through DNA methyltransferases (DNMTs)44. One of the most studied genes in 
AML is the DNA (cytosine-5)-methyltransferase 3A (DNMT3A) that catalyses de novo 
methylation of cytosine residues in DNA45,45. DNMT3A mutations occur in 20-30% of de 
novo AML patients and are associated with an adverse risk46. In addition, chromatin 
modelling enzymes, which mediate posttranslational histone methylation or acetylation 
in order to modify transcription, have been shown to affect tumour development47.  
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1.3.3. Histone Modifications 
 
In addition to DNA methylation, the posttranslational modification of histones plays a 
crucial role in epigenetic regulation. Histones offer a framework for storage space of DNA 
within eukaryotic nucleus. This complex of DNA and histone proteins is called chromatin. 
Histone proteins represent the core element of the nucleosome, the basic component of 
chromatin48. Modification of histone residues can be associated with either genetic 
repression or activation. For example, acetylation of H4K14, methylation of H3K4 or 
phosphorylation of H3S10 all infer genetic activation of specific target genes49. In 
contrast, the methylation of H3K9 and H3K27 is mostly associated with genetic 
repression50. The adjunct of methyl groups to lysine and arginine residues of histone 
proteins is accomplished by histone-lysine methyltransferases and histone-arginine 
methyltransferases, respectively51,52. Rearrangements of the lysine-methyltransferase 2A 
(MLL/KMT2A) gene are one of the first aberrations in methyltransferases that has been 
associated with leukemogenesis; alterations in this gene have been linked to a poor 
prognosis53. Subsequently, different kinds of modifiers coordinating histone methylation 
have been found to be altered in AML. The human lysine-methyltransferase protein family 
is a group of 52 described methyltransferases, sharing a catalytic domain which uses S-
adenosyl-l-methionine (SAM) as methyl donor. Each histone-lysine-methyltransferase is 
highly specific for the associated histone residue54,55 and the catalytic activity drives  
mono-, di- and tri-methylated lysine and causes specific downstream effects reliant on the 
residues’ position and the level of methylation56.  Enzymes, which control histone 
methylation can be classified in histone-methyltransferases and histone-demethylases, 
which both have been reported to be altered in different kinds of cancer57–64.   
 
1.3.4. Epigenetic Targeted Therapy  
 
Given the importance of epigenetic regulation in the physiological background of cells, 
epigenetics plays an important role in the pathogenesis of many diseases. These include 
cancer43,46,47,64–67, including haematopoietic malignancies65,68, where they have been 
extensively studied. Since the understanding of epigenetic regulation in tumour 
emergence and maintenance is rapidly growing, epigenetic targeted therapy concepts are 
of high interest. Several therapeutic approaches targeting epigenetic regulators in AML 
have been productively tested in preclinical studies and some medications have been 
 Error! Use the Home tab to apply Überschrift 1 to the text that you want to appear here. 
  - 11 - 
passed, including, e.g., hypo-methylating agents such as azacytidine (AZA) or decitabine 
(DAC)66,67. Results have been disappointing considering these apporaches69. Both AZA 
and DAC are pyrimidine analogues functioning as inhibitors for DNA-methyltransferases, 
leading to global hypomethylation of cytosine residues70.  Additionally,  drugs affecting 
the activity of histone methyltransferases have been investigated extensively71. Several 
small molecule inhibitors for the DOT1-like histone H3K79 methyltransferase (DOT1L) 
showed a high suppression of HOX (homeobox) genes, leading to induction of 
differentiation and anti-leukemic activity in DNMT3A mutant AML72. Furthermore the 
development of specific inhibitors of the lysine-specific histone demethylase 1A (LSD1) 
have been the objective of many different recent studies73 and have been proven to show 
anti-leukemic properties64,74. Additionally, combinatorial inhibition treatment of histone 
modifying proteins have been proposed, including e.g., combination treatment of LSD1 
and EZH2 (Enhancer of zeste-homologue 2)75 or LSD1 and pan-histone deacetylase 
(HDAC) inhibitors75. Epigenetic targeted therapy concepts therefore are of high 
importance and support patient-adapted therapy concepts in the future treatment of 
AML.   
 
1.4. The Protein-Lysine Methyltransferase EZH2 
 
Enhancer of zeste-homologue 2 (EZH2) is a protein-lysine methyltransferase and the 
central core unit of the polycomb repressive complex 2 (PRC2)76. Through its catalytic 
Su(var)3-9, Enhancer-of-zeste and Trithorax (SET) domain, the methylation of histone H3 
lysine K27 (H3K27me) is achieved, whereby the generation of heterochromatin limits the 
accessibility for the transcription machinery (Figure 3)77. As a result, EZH2 mediates 
transcriptional repression of associated target genes78. EZH2 is capable of mono-, di- and 
tri-methylation of H3K27, which has been linked to a large range of biological functions 
such as transcriptional regulation in haematopoiesis, cellular differentiation and 
development79–81. For example, EZH2 activity is highly important for the maintenance of 
normal differentiation in ES cells79. EZH2 and H3K27 methylation also play a crucial role 
in X-inactivation82, the silencing of one X-chromosome in female development.  
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Figure 3: PCR2 mediated gene repression through catalytic activity of EZH2. By its catalytic SET 
domain EZH2 controls H3K27me3 and thereby promotes gene repression of associated target genes 
through changes in chromatin condensation by transmitting a methyl group from the cofactor S-adenosyl-
L-methionine (SAM)80.  
 
 
EZH2 as part of PRC2 is primarily responsible for the methylation of H3K27. Therefore it 
is important that all PRC2 members are present, although the function of EED, 
RB/AP46/48 and SUZ12  is not yet completely characterized78. It has been discussed for 
years that PRC2 fulfils important roles in normal haematopoiesis by maintaining 
pluripotency and self-renewal capabilities in adult stem cells76,83, therefore indicating that 
EZH2 expression is important for maintaining the stemness of HSCs. Meanwhile, it has 
been proposed that PRC2 mediated tri-methylation marks on H3K27 recruit PRC1 to 
mono-ubiquitinylate lysine 119 of histone H2A in order to establish a higher 
condensation of the chromatin76 revealing an epigenetic signalling pathway downstream 
of H3K27 methylation by EZH2.  
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1.4.1. EZH2 and Cancer 
 
To date, an oncogenic role of EZH2 (Figure 4) is well established in many diverse kinds of 
cancers84–86, whereas the value of EZH2 in haematopoietic malignancies remains unclear. 
High expression of EZH2 in patient samples was first detected in breast87 and prostate88 
cancer in the early 2000s and was connected with a poor prognosis. It has been shown, 
that high levels of EZH2 can be linked to aggressive cell proliferation in endometrial, 
cutaneous melanoma and prostate cancers89. High EZH2 expression is also associated 
with bladder cancer90, a poor prognosis and cisplatin resistance in ovarian cancer84, fast 
progression of lung cancer86 and liver cancer91. Additionally, researchers have observed 
high levels of EZH2 in later stages of brain tumours85, and to be associated to poor 
prognosis in renal92 and gastric93 cancer and chemo-resistance in pancreatic cancer94. 
Furthermore, in 2013, investigators described a link between high expression levels and 
invasion in nasopharyngeal carcinoma95. Especially in lymphomas, high expression levels 
correlate with rapid and aggressive tumour growth96,97.  
 
Figure 4: Schematic illustration of the protein-lysine methyltransferase EZH2. Functional domains are 
coloured, the catalytic SET domain is located C-terminal. Binding domains for the PRC2-proteins EED and 
SUZ12 are indicated above.  
 
Strikingly, hot spot mutations (mainly located in the SET domain) causing increased levels 
of H3K27me3 have been found in 22% of diffuse large B-cell lymphoma (DLBCL) and 7.5-
25% follicular lymphoma (FL)98,99. Y646 mutations occur most frequently in lymphomas; 
significantly higher levels of tri-methylated H3K27 are observed in mutated patient 
samples. Surprisingly, decreased levels of di-methylated H3K27 can be detected, which 
were found to be based on a diminished recognition of unmodified and mono-methylated 
H3K27100. Y646 was first thought to act as LOF mutation, since in vitro testing revealed 
decreased tri-methylation levels of H3K27. In 2010, Sneeringer et al. investigated known 
lymphoma associated EZH2 mutations and found that mutated EZH2 alleles are always 
found associated with one wildtype allele. Thus, wildtype and mutant alleles collaborate 
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to hyper-tri-methylate H3K27, highlighting the importance of a heterozygous status101. 
Referring to this, potent small-molecule inhibitors have been developed and provide a 
promising therapeutic value in phase 1 trials (NCT02082977, NCT01897571). It has been 
definitely shown, that loss or inhibition of H3K27me3 contributes to the development of 
malignancies. In contrast to lymphomas, EZH2 LOF mutations have been found in myeloid 
malignancies such as MDS or AML43,102,103. Ernst et al. described 7q deletions occurring in 
combination with homozygous EZH2 deletions in 9 out of 12 patients, suggesting 
that EZH2 acts as a tumour suppressor in the context of myeloid malignancies. 
Additionally, loss of functional EZH2 has also been detected in patients suffering from 
myelodysplastic syndrome (MDS)103 and EZH2 LOF mutations were likewise correlated 
with a poor prognosis in a cohort of patients with myelofibrosis104.  
These data lead to the hypothesis, that EZH2 can act as a tumour suppressor and oncogene 
– strongly dependent on the cellular context. Within the last few years, contradictory 
results have been presented, also discussing an oncogenic role of EZH2 in MLL-
rearranged leukaemias105. A recent study investigated opposing roles of EZH2 in initiation 
and maintenance of AML, suggesting that expression of EZH2 is highly dependent on the 
stage of disease106.  
 
  
 Error! Use the Home tab to apply Überschrift 1 to the text that you want to appear here. 
  - 15 - 
2.   Materials and Methods 
2.1. Material  
2.1.1.  Laboratory Equipment 
 
Table 1: Applied equipment 
Equipment Provider  
  
ABI 3730 XL Sequencer Applied Biosystems (Foster City, CA, USA) 
Amaxa Nucleofector II device Lonza (Basel, CH) 
Analytical balance ABJ 220-4NM Kern & Sohn (Balingen-Frommern, Germany) 
BioPhotometer Eppendorf (Hamburg, Germany) 
Bio-Rad Mini Protean Tetra blotting system Biorad (Hercules, CA, USA) 
Centrifuge 5415D, 5424R Eppendorf (Hamburg, Germany) 
CO2 incubator C 170 BINDER (Tuttlingen, Germany) 
E-BOX VX2 Vilber Lourmat (Eberhardzell, Germany) 
FACS Vantage SE BD Biosciences (Franklin Lakes, NJ, USA) 
Fluorescent microscope DMi8 Leica Microsystems (Wetzlar, Germany) 
Freezer -20°C Liebherr (Bulle FR, Switzerland) 
Freezer -80°C, TLE Thermo Fisher Scientific (Waltham, MA, USA) 
Freezing container Mr. Frosty Thermo Fisher Scientific (Waltham, MA, USA) 
Fusion SL4 imaging system Vilber Lourmat (Eberhardzell, Germany) 
Heating block Thermomixer compact Eppendorf (Hamburg, Germany) 
X1R Centrifuge Hareaus Thermo Fisher Scientific (Waltham, MA, USA) 
Ice machine FM-170AKE Hoshizaki (Amsterdam, NL) 
Incubator 9040-0013 Binder (Tuttlingen, Germany) 
Liquid Nitrogen Tank Cryoson (Schöllkrippen, Germany) 
Magnetic stirrer MR3001 Heidolph (Schwabach, Germany) 
Microplate reader GloMax® Discover Promega (Madison, WI, USA) 
Microscope ID03 Carl Zeiss (Oberkochen, Germany) 
PCR cycler PeqSTAR 2xGradient Peqlab (Wilmington, DE, USA) 
pH meter inoLab® pH 7110 WTW (Weilheim, Germany) 
Pipettes (0.25-2.00μL, 2.0-20.0μL, 20-
200μL, 200-1000μL) 
Gilson (Limburg, Germany) 
Pipetus accu-jet pro Brand (Wertheim, Germany) 
High precision scale PCB 2500-2 Kern & Sohn (Balingen-Frommern, Germany) 
RS-TR 5 Tube-roller Phoenix instrument (Garbsen, Germany) 
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Nanodrop spectrophotometer 1000 Thermo Fisher Scientific (Waltham, MA, USA) 
Ultrapure water system Milli-Q System Merck Millipore (Darmstadt, Germany) 
VARIOKLAV Type 500 HP Medizintechnik (Oberschleißheim, 
Germany) 
Vertical Autoclave VX-150 Systec (Linden, Germany) 
Vi-CELLTM Cell Viability Analyser XR Beckman Coulter (Krefeld, Germany) 
Vortexer Cenco (Breda, NL) 
Water Bath Type 1003 GFL (Burgwedel, Germany) 
Xcell SureLock Mini Cell Invitrogen (Darmstadt, Germany) 
 
2.1.2.  Consumables 
 
Table 2: Used consumables 
Consumable  Provider  
  
5mL Round Bottom Polystyrene Tube Thermo Fisher Scientific (Waltham, MA, 
USA) 
5mL Stripette serological Pipets Corning (Corning, NY, USA) 
10mL Stripette serological Pipets Corning (Corning, NY, USA) 
25mL serological Pipets Greiner Bio One (Frickenhausen, Germany) 
96-well PCR plate Brand (Wertheim, Germany) 
96-well V-bottom Greiner Bio One (Frickenhausen, Germany) 
Amersham Protran Nitrocellulose 
membrane, 0.45μM 
GE Healthcare (Little Chalfont, UK) 
Combitips advanced 0.5mL Eppendorf (Hamburg, Germany) 
Combitips advanced 1.0mL Eppendorf (Hamburg, Germany) 
Combitips advanced 5.0mL Eppendorf (Hamburg, Germany) 
Diamond Tower Pack D10 Gilson (Middleton, WI, USA) 
Diamond Tower Pack D200 Gilson (Middleton, WI, USA) 
Diamond Tower Pack D1000 Gilson (Middleton, WI, USA) 
Disposable bags Brand (Wertheim, Germany) 
DURAN GL 45 Lab Bottles (100mL, 
250mL, 500mL, 1000mL) 
DURAN Group (Mainz, Germany) 
DURAN Erlenmeyer flasks (50 
mL, 250mL, 500mL, 1000mL) 
DURAN Group (Mainz, Germany) 
Sorenson low binding standard tips Sigma-Aldrich (St. Louis, MO, USA) 
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Gel-loading pipet tips Sigma-Aldrich (St. Louis, MO, USA) 
Micro tube 1.5mL SafeSeal Sarstedt (Nümbrecht, Germany) 
Micro tube 2.0mL SafeSeal Sarstedt (Nümbrecht, Germany) 
Novex Empty Gel Cassette, mini, 1.0 
mm 
Thermo Fisher Scientific (Waltham, MA, 
USA) 
Cryo Tube Vial Thermo Fisher Scientific (Waltham, MA, 
USA) 
PARAFILM Sigma-Aldrich (St. Louis, MO, USA) 
PCR tubes 0.2mL Biozym Scientific (Oldendorf, Germany) 
Petri dish 10cm / 30 cm  Sarstedt (Nümbrecht, Germany) 
TC Flask T25, T75, T175, standard Sarstedt (Nümbrecht, Germany) 
TC Flask T25, T75, T175, suspension Sarstedt (Nümbrecht, Germany) 
TC Plate 6-well - 96-well, standard Sarstedt (Nümbrecht, Germany) 
TC Plate 6-well - 96-well, suspension  Sarstedt (Nümbrecht, Germany) 
Tube 15mL, 120x17mm Sarstedt (Nümbrecht, Germany) 
Tube 50mL, 114x28mm Sarstedt (Nümbrecht, Germany) 
Vasco Nitrile Blue Gloves B. Braun (Melsungen, Germany) 
 
2.1.3.  Chemicals 
 
Table 3: Used chemicals 
Reagent Provider  
  
1 kb ladder  Promega (Madison, WI, USA) 
ß-Mercaptoethanol Sigma-Aldrich (St. Louis, MO, USA) 
2-Propanol AppliChem (Darmstadt, Germany) 
Agarose Carl Roth (Karlsruhe, Germany) 
Albumin Fraction V (pH 7.0) (BSA) AppliChem (Darmstadt, Germany) 
APS (Ammonium persulfate) Carl Roth (Karlsruhe, Germany) 
Ampicillin sodium salt Sigma-Aldrich (St. Louis, MO, USA) 
Aprotinin  Sigma-Aldrich (St. Louis, MO, USA) 
Bio-Rad Protein Assay Dye  Bio-Rad (Hercules, CA, USA) 
Bromophenol blue Sigma-Aldrich (St. Louis, MO, USA) 
Calcium Chloride 2-hydrate AppliChem (Darmstadt, Germany) 
CutSmart Buffer New England Biolabs (Frankfurt, Germany) 
Coulter Clenz Cleaning Agent Beckman Coulter (Krefeld, Germany) 
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Coulter Isoton II Diluent Beckman Coulter (Krefeld, Germany) 
DNase I Roche (Basel, CH) 
DEPC-treated water Thermo Fisher Scientific (Waltham, MA, USA) 
DH5α competent bacteria Thermo Fisher Scientific (Waltham, MA, USA) 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich (St. Louis, MO,USA) 
DMEM high glucose, Gibco Thermo Fisher Scientific (Waltham, MA, USA) 
Ethanol Merck Millipore (Darmstadt, Germany) 
Fetal Bovine Serum (FBS) PAN-Biotech (Aidenbach, Germany) 
Gel Loading Dye Purple 6x New England Biolabs (Frankfurt, Germany) 
HBS 2x Sigma-Aldrich (St. Louis, MO, USA) 
HEPES AppliChem (Darmstadt, Germany) 
Kanamycin Sulfate Sigma-Aldrich (St. Louis, MO, USA) 
LB-Agar  Carl Roth (Karlsruhe, Germany) 
LB-Medium  Carl Roth (Karlsruhe, Germany) 
Lipofectamine 3000 Thermo Fisher Scientific (Waltham, MA, USA) 
Methanol Carl Roth (Karlsruhe, Germany) 
Milk powder (for blotting) Carl Roth (Karlsruhe, Germany) 
MyTaq Polymerase Bioline (London, UK) 
Opti-MEM I Reduced Serum 
Medium, Gibco 
Thermo Fisher Scientific (Waltham, MA, USA) 
PageRuler Prestained Protein 
Ladder 
Thermo Fisher Scientific (Waltham, MA, USA) 
PBS Dulbecco w/o Mg2+, Ca2+ PAN-Biotech (Aidenbach, Germany) 
Penicillin-Streptomycin, Gibco Thermo Fisher Scientific (Waltham, MA, USA) 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich (St. Louis, MO, USA) 
Pierce ECL Plus Western Blotting 
Substrate 
Thermo Fisher Scientific (Waltham, MA, USA) 
Proteinase K New England Biolabs (Frankfurt, Germany) 
Quick-Load Purple 50bp DNA 
ladder 
New England Biolabs (Frankfurt, Germany) 
Recombinant Human FLT3 
(rhFLT3) Ligand 
R&D Systems (Minneapolis, MN, USA) 
Recombinant Human IL3 (rhIL3) 
protein 
R&D Systems (Minneapolis, MN, USA) 
Recombinant Human 
Thrombopoietin (rhTPO) protein 
R&D Systems (Minneapolis, MN, USA) 
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Recombinant Human SCF (rhSCF) 
protein 
R&D Systems (Minneapolis, MN, USA) 
RNase AWAY Carl Roth (Karlsruhe, Germany) 
Rotiphorese gel 30 Carl Roth (Karlsruhe, Germany) 
RPMI 1640 + Glutamax, Gibco Invitrogen (Darmstadt, Germany) 
Sodium chloride (NaCl) Carl Roth (Karlsruhe, Germany) 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich (St. Louis, MO, USA) 
Sodium fluoride NaF Sigma-Aldrich (St. Louis, MO, USA) 
Sodium Orthovanadate  Sigma-Aldrich (St. Louis, MO, USA) 
Sodium pyruvate 100mM Biochrom (Berlin, Germany) 
S.O.C. Medium Invitrogen (Darmstadt, Germany) 
StemPro-34 SFM Media Thermo Fisher Scientific (Waltham, MA, USA) 
SYBR Safe DNA gel stain Invitrogen (Darmstadt, Germany) 
TAE Buffer 10x Apotheke Klinikum der Universtität München 
(Munich, Germany) 
TBS Buffer 10x Apotheke Klinikum der Universtität München 
(Munich, Germany) 
Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich (St. Louis, MO, USA) 
Tris-(hydroxymethyl)- 
aminomethane (TRIS) 
Carl Roth (Karlsruhe, Germany) 
Triton X-100 Sigma-Aldrich (St. Louis, MO, USA) 
Trypan Blue Sigma-Aldrich (St. Louis, MO, USA) 
Trypsin-EDTA (0.05%), phenol red Thermo Fisher Scientific (Waltham, MA, USA) 
Tween20 Sigma-Aldrich (St. Louis, MO, USA) 
 
2.1.4.  Kit Systems 
 
Table 4: Applied kits 
Kit Application Provider  
   
Cell line Nucleofector Kit V Transfection of suspension cell 
lines 
Lonza (Basel, CH) 
Endofree Plasmid Maxi Kit Maxi preparation of plasmid 
DNA  
Qiagen (Hilden, 
Germany) 
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EpiQuik Total Histone 
Extraction Kit 
Isolation of histone proteins Epigentek 
(Farmingdale, NY, USA) 
InFusion HD Plus Cloning Vector cloning Takara Bio (Saint-
Germain-en-Laye, 
France) 
Mouse Cell Depletion Kit Purification of human cells from 
PDX material   
Miltenyi Biotec 
(Bergisch Gladbach, 
Germany) 
MycoAlert Mycoplasma 
Detection Kit 
Detection of mycoplasma 
contamination in cell culture 
Lonza (Basel, CH) 
QIAamp DNA Blood Mini Kit Isolation of gDNA from cells and 
tissues 
Qiagen (Hilden, 
Germany) 
QIAprep Spin Miniprep Kit 
 
Mini preparation of plasmid 
DNA  
Qiagen (Hilden, 
Germany) 
QIAquick Gel Extraction Kit DNA extraction from agarose 
gels 
Qiagen (Hilden, 
Germany) 
QIAquick PCR Purification Kit Amplicon purification Qiagen (Hilden, 
Germany) 
QuikChange II Site directed 
mutagenesis Kit 
Gene mutagenesis Agilent Technologies 
RNAse-Free DNase Kit DNase digest for RNA isolation 
pre-treatment 
Qiagen (Hilden, 
Germany) 
RNeasy Mini Kit  RNA isolation  Qiagen (Hilden, 
Germany) 
SALSA MLPA MDS Kit  MLPA for human cell lines and 
patient material  
MRC Holland 
(Amsterdam, 
Netherlands) 
 
2.1.5  Buffers and Solutions 
 
Table 5: Used buffers and solutions 
Buffer Composition  
  
Agarose gels (1% - 1.5%) 1-1.5% agarose in 1x TAE buffer with SYBR Safe (1:10 
000) 
Western blot buffer (Transfer) 10x  15g Tris, 71g Glycine, 790 g Methanol  
 Error! Use the Home tab to apply Überschrift 1 to the text that you want to appear here. 
  - 21 - 
 
2.1.6.  Antibodies 
 
Table 6: Used primary antibodies 
Antibody Host Dilution Blocked in  Provider 
     
α-EZH2  Rabbit 1:1000 5% Milk Cell Signaling Technology 
(Danvers, MA, USA) 
Add up to 5000 mL d2H20 
Gel electrophoresis buffer 10x 151.4mg Tris, 720.7g Glycine, 50g 
Sodiumdodecylsulfate (SDS), Add up to 5000mL d2H20 
Gel electrophoresis buffer 1x 100 mL gel electrophoresis buffer 
900 mL d2H20 
KCM 5x 5mL 3 M KCl, 4,5mL 1 M CaCL2, 7,5mL 1M MgCl2 
LB agar plates 32g Agar, add up to 1l d2H20 
LB medium Add up to 1l d2H20 
LBampicillin plates LB-Agar 20mL  
100μg/mL Ampicillin 
LämmLi buffer 4x 50mM tris-HCL pH 6.8, 0.8g sodiumdodecylsulfate 
(SDS), 10% glycerol, 1% ß-mercatoethanol, 12.5mM 
EDTA, 8mg bromophenol blue  
TAE buffer 1x 100mL TAE buffer 10x, 900mL d2H20 
TBS 10x 60.57g Tris, 483.3g Sodium chloride 
TBS-T 100mL TBS buffer 10x, 900mL d2H20, 1% Tween-20 
Tris pH 6.8 5L: 908.55g Tris (pH 6.8), add H20 dest. 
Tris pH 8.8 5L: 908.55g Tris (pH 8.8), add H20 dest. 
Lysis buffer for whole cell lysis 25mL 1 M HEPES, pH 7.5, 15mL 5 M NaCl 
2,5mL 200 mM EGTA, 100mL 50% Glycerol 
5mL Triton X-100, 2.1g NaF, 2.2g Na4P2O7x10H2O add 
d2H20 
freshly added before each lysis: 5mM PMSF, 25 μg/mL 
Aprotinin,, 50μg/mL Sodium Orthovanadate 
FACS buffer PBS, 1% FCS, 1mg/l propidium iodide 
Storage: Light protected, at 4°C 
Freezing buffer 10% DMSO in FBS, stored at 4°C 
Blocking solutions 5% non-fat milk in TBS-T or 5% BSA in TBS-T 
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α-ß-Actin Mouse 1:20.000 5% Milk Sigma-Aldrich (St. Louis, MO, 
USA) 
α-H3K27me3 Rabbit 1:1000 5% BSA Cell Signaling Technology 
(Danvers, MA, USA) 
α-H3 total  Rabbit 1:30.000 5% Milk Abcam (Cambridge, UK) 
α-EED Rabbit 1:500 5% Milk MerckMillipore (Burlington, US) 
α-SUZ12 Rabbit 1:1000  5% Milk Cell Signaling Technology 
(Danvers, MA, USA) 
α-RbAP46 Rabbit  1:1000 5% BSA Cell Signaling Technology 
(Danvers, MA, USA) 
 
Table 7: Used secondary antibodies 
Antibody Host Dilution Provider 
    
Goat Anti Mouse m-
IgGkappa HRP  
 
Goat 1:10.000 Santa Cruz Biotechnology (Dallas, 
TX, USA) 
Goat Anti Rabbit Goat 1:10.000 Sigma-Aldrich (St. Louis, MO, 
USA) 
 
2.1.7  Oligonucleotides 
 
Table 8. Oligonucleotides for EZH2 sequencing  
Name 5’ → 3’ sequence Tm 
   
EZH2-IsoA-FOR1  CCTTCTGATAAAATTTTTGAAGCC 59.6°C 
EZH2-IsoA-FOR2 GACAATTTCTGTGCCATTGCT 60.1°C 
EZH2-IsoA-FOR3 CGCAAGGGTAACAAAATTCG 60.5°C 
EZH2-IsoA-REV1 GCTGCTGTTCGGTGAGTTCT 60.6°C 
 
Table 9: Oligonucleotides for mutagenesis 
Name 5’ → 3’ sequence Tm 
   
EZH2/A692G FOR CCGTTAACCATCATAACTTTTCCATAGCAGTTTGGATTT
ACCG 
79.7°C 
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EZH2/A692G REV CGGTAAATCCAAACTGCTATGGAAAAGTTATGATGGTT
AACGG 
79.7°C 
EZH2/Y646N FOR TGAGAAATAATCTCTCCACAGTTTTCTGAGATGAATTCA
TTTTTCTG 
78.1°C 
EZH2/Y646N REV CAGAAAAATGAATTCATCTCAGAAAACTGTGGAGAGAT
TATTTCTCA 
78.1°C 
EZH2/Y731F FOR GCCTGGCTGTATCTGAAATCAAAAAACAGCTCTTCGC 79.4°C 
EZH2/Y731F REV GCGAAGAGCTGTTTTTTGATTTCAGATACAGCCAGGC 79.4°C 
EZH2/I744fs FOR CCCTGAAGTATGTCGGCATGGCATCGAAAGAGAAATGG
A 
78.0°C 
EZH2/I744fs REV TCCATTTCTCTTTCGATGCCATGCCGACATACTTCAGGG 78.0°C 
EZH2/c.2195+1 FOR AGCTGTTTTTTGATTACAGATTGATACAGCCAGGCTGAT
GC 
78.3°C 
EZH2/c.2195+1 REV GCATCAGCCTGGCTGTATCAATCTGTAATCAAAAAACAG
CT 
78.3°C 
EZH2/G743fs FOR CCATTTCTCTTTCGATGCCGGGGCCCGACATACTTCAGG
GC 
79.2°C 
EZH2/G743fs REV GCCCTGAAGTATGTCGGGCCCCGGCATCGAAAGAGAAAT
GG 
79.2°C 
EZH2/K574E FOR GCACGGGCACTGCTCGGTGTTGCACTGTG 80.2°C 
EZH2/K574E REV CACAGTGCAACACCGAGCAGTGCCCGTGC 80.2°C 
EZH2/D293G FOR ACGATGTAGGAAGCATTCATATTTAAAACATCGCCTACA
GAAAAG 
78.9°C 
EZH2/D293G REV CTTTTCTGTAGGCGATGTTTTAAATATGAATGCTTCCTA
CATCGT 
78.9°C 
EZH2/Q612X FOR  TCCTGCAAGAACTGCAGTATTTAGCGGGGCTCC 80.4°C 
EZH2/Q612X REV GGAGCCCCGCTAAATACTGCAGTTCTTGCAGGA 80.4°C 
EZH2/D730_Y731FOR CTGGCTGTATCTGTAATCAAAAAAACAGCTCTTCGCCA 78.3°C 
EZH2/D730_Y731REV TGGCGAAGAGCTGTTTTTTTGATTACAGATACAGCCAG 78.3°C 
 
Table 10: Oligonucleotides for cloning 
Name 5’ → 3’ sequence Tm 
   
InFuEZH2pcDNA6 FOR CAGTGTGGTGGAATTCCGAAGAATAATCATGGGCCAGA
CT 
78.0°C 
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InFuEZH2pcDNA6 REV GCCCTCTAGACTCGAGGCAGATGTCAAGGGATTTCCAT
TTC 
80.0°C 
InFuEZH2piggy FOR CTCTGAGGCCACCCGATAATCATGGGCCAGACTGGGAA
GAA 
82.0°C 
InFuEZH2piggy REV AGGCTTACCGCGGCCATGTCAAGGGATTTCCATTTCTCT
TTCG 
81.0°C 
 
Table 11: Oligonucleotides for CRISPR/Cas9 mediated genome editing 
Name 5’ → 3’ sequence Tm 
   
EZH2 guide upper   CACCGACCAAGAATGGAAACAGCGA 67.0°C 
EZH2 guide lower AAACTCGCTGTTTCCATTCTTGGTC 64.0°C 
EZH2 Screening FOR ACAATTTCTCCTTTCCTCTCCTTCA 63.0°C 
EZH2 Screening REV  TGGACACCCTGAGGTCAATGAT 62.0°C 
2.1.8 Vectors 
Table 12: Used vector systems 
Vector Application  Origin 
   
EZH2 (NM_004456) Entry vector Origene (Rockville, US) 
pcDNA6/HisA Expression-vector for transient 
expression  
AG Spiekermann, Klinikum 
der Universität München   
pcDNA6/HisA-EZH2 Re-expression of EZH2 mutations 
for tri-methylation activity test 
This work  
tet-3xFLAG-AsiSI-NotI-
IRES-DsRed-Express-
M2rtTA-P2A-PuroR 
Expression vector for PiggyBac  AG Bultmann, LMU 
tet-3xFLAG-AsiSI-NotI-
IRES-DsRed-Express-
M2rtTA-P2A-PuroR-EZH2 
Stable/inducible re-expression of 
EZH2 in K562 cells 
This work  
pSpCas9(BB)-2A-GFP-
gRNA 
Expression vector for Cas9 
endonuclease 
AG Bultmann, LMU 
pSpCas9(BB)-2A-GFP-
gRNA-EZH2 
Generation of EZH2 knockout cell 
clones  
This work  
Transposase Helper plasmid for stable gene 
insertion via PiggyBac  
AG Bultmann, LMU 
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2.1.9 Cytostatics and Inhibitors 
 
Stock solutions of the cytostatic cytarabine (AraC, Selleck Chemicals, Houston, TX, USA) 
at 20mM and EZH2 inhibitor GSK126 (Selleck Chemicals, Houston, TX, USA) at 10mM 
were prepared by dissolving the drugs in DMSO. All steps were performed under sterile 
conditions. The anthracycline daunorubicin was prepared at 3.2mM dissolved in 
deionized water under sterile conditions. Aliquots were stored at -80°C to avoid freeze-
thaw-cycles.  
2.1.10 Software 
 
Table 13: Applied software 
Software  Application  Provider  
   
Microsoft Office 2010 Data analysis (such as 
sequencing), text editing  
Microsoft (Redmond, WA, 
USA) 
SnapGene 3.3.4 Primer design, sequencing 
analysis, creation of vector 
maps  
GSL Biotech LLC (Chicago, 
IL, USA) 
IBS  Design and presentation of 
shown biological sequences  
CUCKOO Workgroup, online 
Benchling Design of guideRNAs, 
sequencing analysis  
Benchling Inc., online 
E-Capt 15.06 Agarose gel recording and 
documentation  
Vilber Lourmat (Eberhardzell, 
Germany) 
GraphPad Prism 6.07 Data visualization, statistical 
analysis  
GraphPad Software (La Jolla, 
CA, USA) 
ImageJ version 1.50d Western blot quantification  ImageJ developers, online 
Genemarker V2.6.0 Analysis of MLPA results  Softgenetics LLC.(State College, 
USA) 
FusionCapt Advance 
16.11 
Western blot recording and 
analysis  
Vilber Lourmat (Eberhardzell, 
Germany) 
Biorender  Illustration and design of 
biological figures   
Biorender AG (Münchwilen TG, 
CH) 
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2.2. Methods 
 
2.2.1. Cell Culture Methods  
2.2.1.1 Cell lines and Patient Samples  
 
All cell lines (Table 14) were acquired from DSMZ (Braunschweig, Germany) and cultured 
according to the supplier’s recommendation. PDX-AML samples were engrafted and 
passaged in mice and re-isolated for in vitro cultivation as it has been previously 
described107. Exclusion of mycoplasma contamination was assessed continuously during 
cell culture using the MycoAlert Mycoplasma detection kit (Lonza, Basel, CH). Used 
patient material was derived from AML patients from the trials AMLCG-99 
(NCT00266136) and AMLCG-2008 (NCT01382147), and the Department of Medicine III, 
University Hospital, LMU, Großhadern. Informed permission for utilization of sample 
material was obtained from all participants in agreement with the Declaration of Helsinki. 
 
Adherent cells: 
Adherent cells were incubated with DMEM (Dulbecco), supplemented with 10% FBS, 
0.5% penicillin/streptomycin at 37°C and 5% CO2. Before usage, cells were always re-
suspended with pre-warmed medium and only used for further experiments when 
viability was more than 90%. Cell viability was measured with the Vi-Cell Cell Viability 
Analyser (Beckman Coulter, Krefeld, Germany). For sub-cultivation of cells were washed 
one with PBS (room temperature) and then covered with trypsin-EDTA at room 
temperature for 2-3 min to ensure detachment of the cells from the flask ground. Adding 
DMEM stopped the activity of trypsin and the cells can be passaged or harvested for 
further experiments. Adherent cells were sub-cultured in a ratio of 1:10 every 2-3d.  
 
Suspension cells:  
Human cell lines 
All human AML cell lines were incubated with RPMI medium supplemented with 20% FBS 
and 0.5% penicillin and streptomycin at 37°C with 5% CO2. Cell density was kept between 
0.4–1.2 x 106 cells/mL (as recommended by the DSMZ (Braunschweig, Germany)). Cells 
were sub-cultured three times a week. For all experiments and cultivation condition pre-
warmed medium was used. Cells were always re-suspended with pre-warmed medium 
and only used for further experiments when viability was more than 90%. Cell viability 
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was measured with the Vi-Cell Cell Viability Analyser (Beckman Coulter, Krefeld, 
Germany). The cell line K562, originally a CML cell line, was used for the cytotoxicity 
experiments in EZH2 KO cells. K562 originate from a CML patient in the last stage of the 
disease (blast crisis), which phenotypically shows a very high similarity to AML. For this 
reason, the line is particularly suitable for cytotoxicity studies.   
 
Patient-derived xenograft (PDX) cells 
PDX cells were cultured (according to Martin Wermke (Dresden, Blood 2015)) with 
StemPro-34 medium, supplemented with appropriate nutrient supplement, 0.5% 
penicillin/streptomycin, 0.5% L-Glutamine, 2% FBS, 0.02% SCF (stock 50µg/mL), 0.02% 
TPO (stock 50µg/mL), 0.02% IL-3 (stock 50µg/mL) and 0.01% FLT3L (stock 100µg/mL 
PBS + 0.1% BSA). Nutrient supplement was slowly thawed at 4°C. Medium was always 
prepared freshly before PDX cell cultivation. PDX cells were cultivated at 37°C and 5% 
CO2 and medium was always pre-warmed for experiments. Cell viability was measured 
with the Vi-Cell Cell Viability Analyser (Beckman Coulter, Krefeld, Germany). 
              
Table 14: Human cell lines in this thesis   
Name Cultivation Organism Tissue/Tumour Origin 
     
Hek293T Adherent Human Embryonic kidney DSMZ 
HL-60 Suspension Human Acute myeloid leukaemia DSMZ 
K562 Suspension Human Chronic myeloid leukaemia DSMZ 
Kasumi1 Suspension Human Acute myeloid leukaemia DSMZ 
KG1a  Suspension Human Acute myeloid leukaemia DSMZ 
MM1 Suspension Human Acute myeloid leukaemia DSMZ 
MM6 Suspension Human Acute myeloid leukaemia DSMZ 
Molm13 Suspension Human Acute myeloid leukaemia DSMZ 
MV4-11 Suspension Human Acute myeloid leukaemia DSMZ 
Oci AML 3 Suspension Human Acute myeloid leukaemia DSMZ 
Oci AML 5 Suspension Human Acute myeloid leukaemia DSMZ 
Pl-21 Suspension Human Acute myeloid leukaemia DSMZ 
SKM-1 Suspension Human Acute myeloid leukaemia DSMZ 
THP-1 Suspension Human Acute myeloid leukaemia DSMZ 
U937 Suspension Human Histiocytic lymphoma DSZM 
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2.2.1.2 Proliferation Assays 
 
Suspension cells were treated with cytarabine (AraC, Selleck Chemicals, Houston, TX, 
USA), and daunorubicin (DNR, in-house). For short time assays, viable cell number was 
determined after 72h on Vi-Cell Cell Viability Analyser (Beckman Coulter, Krefeld, 
Germany). For long-term proliferation assays, cells were treated three times (d0, d4, d8) 
and viable cells were counted every second day. Unpaired, two-tailed Student’s t-test and 
calculation of all IC50 values were performed using GraphPad Prism version 6.07 
(GraphPad Software, La Jolla, CA, USA). PiggyBac108(PB)/EZH2 cells were pre-cultured 
with or without doxycycline (1μg/mL) for 72h followed by treatment with AraC +/- 
doxycycline, which was added every 48h. For knockdown experiments in PDX cells, siRNA 
EZH2 (#s4918, Thermo Fisher Scientific, Waltham, US) was transiently transfected 
(10nM) via nucleofection. Cells were pre-incubated for 48h and then treated with AraC 
for 72h.  
 
2.2.1.3 Determination of Cell Viability by Trypan Blue Exclusion 
 
To determine the cell viability and cell number, the trypan blue exclusion method was 
used as it is the most common method to define cell counts. The method is based on the 
simple principle, that viable cells actively exclude the dye whereas dead cells are stained 
blueish. Using of this staining viable cells can be distinguished from dead cells which is 
important for the evaluation of drug effects, such as inhibitors or cytostatics on the cell 
viability. Cell count was determined automatically with the Vi-Cell Cell Viability Analyser 
(Beckman Coulter, Krefeld, Germany). Cell number of untreated cells was always 
considered as 100% viability. All other conditions were normalized to the untreated cells 
in each experiment.   
 
2.2.1.4. Freezing and Thawing of Cells  
 
Cells in a density from 2-6 x 106 were made for long time storage in liquid nitrogen. The 
cell pellet was resolved in 1mL freezing medium (FBS supplemented with 10% DMSO) 
and frozen in 1.5mL cryotubes. These tubes were first delivered to -80°C in a suitable 
freezing container to gently cool down at a freezing rate of 1°C/minute. For long time 
storage, the cells were delivered to the liquid nitrogen at -196°C and thawed as required. 
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For thawing, cells were kept warm at 37°C for one minute and afterwards moved to a 
50mL falcon, which contained pre-warmed medium in order to stop cytotoxic effects of 
the DMSO which is contained in the frozen cells. Cells were spun down for 5 min at 300g 
at room temperature and then cultured in the appropriate amount of pre-warmed 
medium.   
 
2.2.1.5. Mycoplasma Detection Assay 
All used cell lines were tested for mycoplasma contamination periodically during cell 
cultivation time. For detection the MycoAlert Mycoplasma Detection Kit from Lonza (Basel, 
CH) was used. Substrate and reaction solution were stored at room temperature for 30 
min before usage. Only the supernatant of the tested cells were centrifuged at 200g for 
five min (approximately 0.5mL). 25µL of the supernatant was transferred to a 
luminescence compatible 96 well plate.  Then 25µL of the reagent solution was added and 
incubated for 5 min at RT in order to lyse mycoplasma cells.  Detection of luminescence 
was performed using the plate reader GloMax Discover (read A). After this first 
measurement 25µL substrate solution were added and incubated for 10 min in the dark. 
Luminescence was measured for a second time after this incubation step where 
mycoplasma enzymes react with the substrate solution. This reaction can be visualized 
due to luciferase enzyme activity. After 10 min, the solution is measured a second time 
(read B). Afterwards, the ratio (B/A) indicates whether cells are contaminated (>1.1.) or 
not (<0.9).  
 
2.2.1.6. Transfection  
 
Transient Transfection  
For transient DNA and RNA transfection in 293T cells, lipofectamine 3000 transfection 
reagent (Thermo Fisher Scientific, Waltham, US) was used. One day before transfection 
293T cells were seeded at a density of 1 x 106 cells per 6-well and incubated at 37°C and 
5% CO2. After 24h medium was changed (2h before transfection). 2µg DNA were 
commonly transfected transiently, according to the suppliers’ protocol.  
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Transient Transfection by Nucleofection  
For transient induction of DNA and RNA into K562 cells the 2b Nucleofector device from 
Lonza (Basel, CH) was used. This method offers cell-type specific nucleus targeted 
nucleotide transfer. For each cell line the recommended protocol which is provided from 
the manufacturer was applied. One day before transfection, cells were seeded out in low 
density 2d before nucleofection (approximately 0.2 x 106 cells/mL, depending on the cell 
type). For transfection procedure, cells were carefully spun down as described in each 
protocol and then suspended in the appropriate nucleofector solution (which was 
complemented with the suitable supplement solution) by carefully pipetting up and 
down. Afterwards, 2 µg DNA were added to the mix and the solution was carefully 
transferred to a provided cuvette. After nucleofection, cells were carefully transferred to 
a 24-well-plate.   
 
 
Analysis of Transfection Efficiency 
In order to evaluate the efficiency in each transfection assay the pmaxGFP vector, which 
is provided in the 2b Nucleofector kits from Lonza (2µL from a 0.5µg/µL solution) was 
applied. After 16-18h the first GFP signal can be seen with the FITC channel (Fluorescence 
microscope Leica DMi8 (Leica Microsystems (Wetzlar, Germany)). 
 
2.2.2 Protein-Biochemical Methods  
2.2.2.1. Whole Cell Lysis  
 
Whole cell lysis was performed as it was described before123. For each lysate, a minimum 
cell amount of 4 x 106 cells was needed. Cells were spun down for 5min at 300g and 4°C 
and pellets were stored on ice for the whole lysis time. Cells were washed twice with ice 
cold PBS and re-suspended until a homogenous mixture was generated. Cells were spun 
down for another 5min at 300g and 4°C. For detachment of adherent cell lines a cell 
scraper was used, in order to generate a cell suspension. The pellet was re-suspended in 
the according amount of lysis buffer, which is supplemented with 5µL aprotinin/mL, 10µL 
PMSF/mL and 10µL orthovanadate/mL of lysis buffer. The pellet was vortexed every 
5min. To remove cell fragments, the suspension was spun down after 30min on ice at 
13.0000 rpm for 30min at 4°C and transferred to a pre-cooled tube. All whole cell lysates 
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were stored at -20°C for long time storage. For all further applications the lysates were 
always kept on ice.  
 
2.2.2.2. Nuclear Cell Lysis  
 
Nuclear cell lysis was performed as it was described before123. All steps were performed 
using the EpiQuik Nuclear Extraction Kit II (Nucleic Acid-Free) from Epigentek 
(Farmingdale, NY, USA) according to the manufacturers’ protocol. After removing the 
medium, cell pellets were washed twice with ice cold PBS and spun down at 300g for 5min 
at 4°C. The appropriate amount of 10x pre-lysis buffer, which was diluted 1:10 in H20 dest. 
was added and a homogenous suspension was generated. For nuclear pellet extraction 
the suspension was incubated for 10min on ice, followed by centrifugation at 12.000 rpm 
at 4°C.  The supernatant was carefully removed and the pellet containing cell nuclei was 
incubated with nuclear lysis buffer for 30min on ice. Afterwards, the nuclear extracts 
were carefully removed and DTT (at a 1:1000 dilution) was added. Nuclear cell lysates 
were stored at -80°C for long time storage.  
 
2.2.2.3. Determination of Protein Concentrations  
 
Determination of protein concentration was performed as it was described before123. 
Protein concentration in cell lysates (whole cell and nuclear) was assessed by using a 
spectrophotometer and the Bradford method as previously described109. The calculated 
absorbance (595nm) correlates with the total protein concentration. First, the dye 
reagent was diluted 1:5 in H2O and protein lysates were diluted 1:10 in H2O. 20μl of these 
diluted lysates were then mixed with 980μl of diluted dye and stored for 5 min at RT. 
Absorption (595nm) was measured and compared to a blank control sample with only 
the dye and H2O. A serial dilution of the BSA solution (200-1000μg/mL) was used as 
reference standard in order to evaluate final concentration.  
 
2.2.2.4. Immunoblotting and SDS-PAGE 
 
Immunoblotting, which is commonly known as Western Blotting (WB), was used for 
detection of proteins and was performed as it was previously described123. First, lysates 
from either whole cell or nuclear fractions were generated as described before. Then, 
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denaturing gel electrophoresis separates different molecular sized proteins. 
Subsequently, separated proteins are transferred to a nitrocellulose membrane. After 
blocking, the membrane is incubated with a solution containing a specific antibody 
against the protein of interest followed by a secondary antibody which is conjugated to a 
detection system. Between 2µg (for nuclear cell fractions) and 20µg (for whole cell 
fractions) of protein were loaded and a sodium dodecyl sulfate-polyacrylamide (SDS) gel 
electrophoresis was performed. Protein concentration was detected by Bradford assay 
with Bio‐Rad Protein Assay reagent. Before electrophoresis 4x Lämmli buffer was added 
and samples were boiled for 10min at 95°C. After electrophoresis, separated proteins 
were moved to a nitrocellulose membrane by wet transfer procedure overnight at 100mA. 
The next day, membranes were blocked in Tris buffered saline (TBS-T) containing 5% 
non-fat dry milk. The same solution was prepared to dilute primary and secondary 
antibody, which were incubated with the membranes for 1h at room temperature. After 
antibody incubation the membranes were always washed three times with TBS-T for five 
min each. For protein detection, ECL method was applied. Seperating gel (here shown for 
10%): H2O dest. 6.9mL; 30% acrylamide/bisacrylamide 4mL; 1.5M Tris-HCl buffer (pH 
8.8) 3.8mL; 10% SDS in H2O dest. 0.15mL; 10% APS in H2O dest. 0.15mL; TEMED 
0.009mL. Stacking gel: H2O dest. 3.4mL; 30% acrylamide/bisacrylamide 0.83mL; 1.5M 
Tris-HCl buffer (pH 6.8) 0.63mL; 10% SDS in H2O dest. 0.05mL; 10% APS in H2O dest. 
0.05mL; TEMED 0.005mL.  
 
2.2.2.5. Evaluation of Biochemical EZH2 Activity  
To investigate the effect of mutations on the catalytic activity of EZH2, eight distinct 
mutations were characterized for their potential to tri-methylate H3K27.  For this assay, 
HEK293T EZH2-/- cells were seeded out in a concentration of 1 x 106 cells per 6-well plate 
one day before transfection. EZH2 mutant or wildtype constructs were transfected 
transiently in HEK293T/EZH2-/- cells.  After 72h, nuclear or whole cell lysates were 
generated and global H3K27me3 levels were evaluated by immunoblotting. Levels of 
H3K27me3 were normalized to the wildtype control for each construct.  
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2.2.3. Genome Editing  
2.2.3.1. CRISPR/Cas9 mediated EZH2 Silencing 
 
Design of single guide RNAs (sgRNA) was performed with Benchling software, 
considering the sgRNA score which gives information about the predicted off-target 
effects. To ensure proper gene knockout, it is advisable to target exons at the anterior site 
of the gene. Therefore, EZH2 sgRNA was designed to target Exon 3 of EZH2.  
 
Figure 5: Targeting EZH2 exon 3 for CRISPR/Cas9 mediated gene knockout. For the establishment of 
CRISPR/Cas9 mediated knockout (KO) clones, exon 3 of EZH2 was targeted. Wildtype/KO clone sequences 
were confirmed by Sanger sequencing for each clone. 
 
Genome editing procedures with CRISPR/Cas9 was performed as is was previously 
described by Stief et. al, 2019123.Establishment of CRISPR/Cas9 mediated EZH2 knockouts 
(KO,Figure 5) in the cell lines HEK293T and K562, cells were transiently transfected with 
2µg pSpCas9(BB)-2A-GFP-gRNA-EZH2 by using electroporation (nucleofection). GFP 
positive cells were accumulated after 2d and single cell (SC) sorted into 96-well plates (V-
bottom, K562) and in 30cm dishes (HEK293T) with the FACSVantage SE. For HEK293T 
cells, the colonies were separated manually using a 20µL sterile pipette tip and 
transferring each cell into wells of a 96-well plate. After that, cells were incubated at 37°C 
with 5% CO2 for a few weeks, until colony formation was observed and sc clones were 
expanded. To screen for EZH2 loss, cells were lysed and amplified exon 3 PCR products110 
were sequenced by Sanger sequencing. gDNA was enriched with the QIAamp DNA Blood 
Mini Kit in a 96-well plate, re-suspended in 50µL lysis buffer SC, chilled for 30min at -
80°C, incubated at 56°C for 3h and finally Proteinase K heat deactivated at 85°C for 30 
a. b.
Supplementary Fig. 4, related to Fig. 4 Resistance in the myeloid EZH2 knockout cell line K562. 4.
a, Correlation between EZH2 protein expression and global H3K27me3 9 hematopoietic cell lines
(Pearson`s correlation; R2=0.5384, *p=0.024). b, Plot showing DNR IC50 values for EZH2wt (n=6) and
EZH2-/- (n=7) single cell clones. Cells were treated with DNR/DMSO for 72 h. Each clone represents the
mean of three independent experiments. c, Plot comparing AraC IC50 values in in EZH2wt (n=6) and
EZH2-/- (n=7) clones. Mean are given for three independent experiments for each clone. d, Longterm low
dose AraC treatment in in EZH2wt (n=3) and EZH2-/- (n=3) clones. Cells were treated with 30 nM
AraC/DMSO for 12 days. Cells were splitted and treated every 4 days. Mean  s.d are given for three
independent experiments for each clone. e, Schematic representation of exon 3 sequencing for
CRISPR/Cas9 screening. Exon 3 was amplified and sequenced by Sanger sequencing. Exemplary
sequencing of EZH2w shown above, EZH2-/- below.
Name DSMZ no:
K562 ACC-10
293T ACC 635
HL-60 ACC 3
KG1a ACC 421
Molm 13 ACC 554
MV4-11 ACC 102
Oci AML 3 ACC 582
Oci AML 5 ACC 247
PL-21 ACC 536
SKM-1 ACC 547
THP-1 ACC 16
d. e.
c.
Supplementary Table 1 
EZH“ mut!  
wt
KO
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min. 2.5µL/well of this lysate were directly subjected to the PCR mixture (25µL/rxn., 
0.1µL MyTaq DNA Polymerase) and PCR was performed under following conditions: 
95°C_5 min- (95°C_30s - 61°C_30s - 72°C_30s) x 45 - 72°C_40s - 4°C_∞.  Genetic EZH2 KO 
was detected for each clone by RFLP analysis of PCR products using digestion with 
HpyAVI. After successful targeting, recognition sites are lost. Expression loss was always 
validated by immunoblotting for each clone. Primer and PCR design was performed using 
both, Geneious 8.1.7 and Benchling software.  
 
2.2.3.2. Re-Expression by PiggyBac (PB)/Transposase System  
 
For inducible re-expression of EZH2 in HEK293T and K562 cells, cells were transfected 
either by lipofectamine (HEK293T) or nucleofection (K562) with tet-3xFLAG-AsiSI-NotI-
IRES-DsRed-Express-M2rtTA-P2A-PuroR-EZH2108. Transposase was expressed 
transiently as helper plasmid. After transfection, cells were incubated for 48h at 37°C and 
5% CO2 and afterwards selected with 2µg/mL puromycin for 3d.  Next, cells were sorted 
into 96-well-plates (with V-bottom) with the FACSVantage SE (single cell clones). Cells 
were incubated at 37°C with 5% CO2 for a few weeks, until colony formation was observed 
and sc clones were expanded. To confirm inducible EZH2 protein expression by 
immunoblottting, clones were treated for minimum 24h with 1µg/mL doxycycline. 
 
2.2.4. Molecular Biological Work 
2.2.4.1. Cloning  
 
For all cloning procedures In-Fusion Cloning (Takara-Bio, Kusatsu, JP) was performed. 
This technique provides a highly efficient, ligation-independent cloning method, which is 
based on the annealing of complementary ends of a cloning insert and linearized cloning 
vector. First, a base vector was chosen and cut by desired restriction enzymes. The insert 
of interest was amplified by specifically designed cloning primers which contain 15bp 
extensions (5’) that are complementary to the ends of the linearized vector. Primer design 
for cloning was performed with the SnapGene 3.3.4 software. After verification of the 
target DNA on an agarose gel, the amplicon was purified by the QIAQuick PCR Purification 
kit. Amplifying PCR was performed under following conditions: 5µL premix, 1µL primer 
FOR (10µM), 1µL primer REV (10µM), 10ng vector with desired insert (template) and xµL 
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H20 dest., 20µL in total. Linearization of the base vector was achieved by restriction digest 
with specific restriction enzymes as followed: 500ng vector, 1.5µL enzyme A, 1.5µL 
enzyme B, 20µL in total.  To ligate the amplified insert to the desired vector, a ligation was 
performed under following conditions: 2µL 5x InFusion HD enzyme premix, 50ng of 
amplified Insert, 150ng of linearized vector, xµL H20 dest.; 10µL in total. Reaction was 
incubated for 15 min at 50°C. Transformation of the cloned construct was performed 
using Stellar heat-shock competent cells (Takara-Bio, Kusatsu, JP) as proposed in the 
protocol. For all transformations 2.5µL of the ligation mix was used. Stellar competent 
cells were thawed on ice and the ligation mix was added. After 30 min on ice the cells were 
heat-shocked for exactly 45 sec at 42°C to enforce DNA uptake to the bacterial strain. After 
two min on ice 500µL SOC medium was added and the bacteria mix was shaken for one 
hour at 37°C and 210 rpm. After that cells were spun down and re-suspended in 100µL 
fresh SOC medium. Diverse dilutions (1:20, 1:50, 1:100, 1:200) were spread out on LBamp 
agar plates and incubated in an appropriate incubator overnight. After plasmid mini 
preparation, the sequence of the cloned insert was always verified.  
 
2.2.4.2. Site-directed Mutagenesis 
 
Site directed mutagenesis was used to induce point mutations, switch amino acids, and 
delete or insert single or multiple amino acids. This technique is a reliable tool which 
allows site-specific mutation insertion in any double-stranded plasmid. For mutation 
insertion the Quickchange II Site directed mutagenesis kit (Agilent Technologies, Santa 
Clara, US) was applied. The basic idea of the procedure relies on specific primers which 
both contain the desired mutation site. The primers are extending the template in a PCR 
reaction during temperature cycling by the PfuUlta HF DNA polymerase, which is provided 
in the kit. This extension produces mutated plasmid DNA of choice. The DPNI 
endonuclease (target sequence: 5’-Gm6ATC-3’) is specific for methylated and hemi-
methylated DNA and digests the parental DNA template, to enrich the mutation-
containing fragments. Mutation inserting PCR was performed under following conditions: 
5µL 10X reaction buffer, 20ng dsDNA template, 125ng Primer FOR, 125ng Primer REV, 
1µL dNTP mix, xµL H20 dest.; 50µL in total. Transformation of the mutated vector is 
recommended in XL-10 blue supercompetent E.coli cells, which are provided in the kit.  
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2.2.4.3. Chemical Transformation of Bacteria 
 
Chemical transformation was used for re-transformation procedure in DH5α bacteria 
(Thermo Fisher Scientific, Waltham, US). This transformation step was used for all re-
transformation procedures to multiply plasmid DNA. Competent bacteria were thawed 
on ice and then 1µL DNA was supplemented. In parallel, 10µL KCM and 14µL H20 dest. 
were added. This mixture was incubated on ice for 20min, followed by 10min incubation 
at room temperature. Subsequent to this, 500µL LB medium were added and the cell 
suspension was shaken for one hour at 37°C and 210 rpm. After this procedure, 50–120µL 
of bacteria suspension were spread out on LBamp plates by means of a drigalski spatula. 
Plates were incubated overnight at 37°C in an appropriate incubator.  
 
2.2.4.4. Isolation of Plasmid DNA – Mini Preparation 
 
Approximately 2mL of a single bacteria clone overnight culture was used for mini 
preparation of plasmid DNA. For all mini preparations the QIAprep Spin Miniprep kit 
(Qiagen, Hilden, Germany) was used. Cells were spun down for 3 min at 6800g and the 
supernatant was discarded. All further steps were performed according to the supplier’s 
protocol. The DNA was eluted by addition of 30-50µL EB buffer and incubation for 3min. 
The eluted DNA was collected in a new 1.5mL tube and the concentration was determined 
by the Nanodrop. Plasmid DNA was stored at -20°C for long-term storage.  
 
2.2.4.5. Isolation of Plasmid DNA – Maxi Preparation 
 
In case that a higher amount of plasmid DNA was needed, a maxi preparation was 
conducted. Therefore, the Endofree Plasmid Maxi kit (Qiagen, Hilden, Germany) was 
applied. To increase bacteria and hence DNA material, a 2mL of a single bacteria clone 
was expanded to 100mL LBamp and shaked in a 1000mL Erlenmeyer flask at 37°C and 
210 rpm overnight. The next day, bacteria were spun down at 6800g for 10 min at 4°C. All 
further steps were performed according to the supplier’s protocol. The pellet was air 
dried for approximately 10 min and afterwards an appropriate amount of H20 dest. (200–
500 µL) were applied on the dried DNA. To increase concentration, an overnight 
incubation step was performed and concentration was determined the next day with the 
Nanodrop. Plasmid DNA was stored at -20°C for long-term storage. 
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2.2.4.6. DNA Restriction Digest 
 
To assess correct cloning or mutagenesis, an enzymatic restriction digest was performed. 
All enzymes were acquired from New England Biolabs (Frankfurt, Germany). All digestion 
setups were applied as recommended by the producer. In a further step, the nucleic acids 
were separated on a 1% agarose gel for visualization with SYBR-Safe and UV light. The 
mix containing the following components were incubated for 2h at 37°C: 1µg plasmid 
DNA, 1µL of each restriction enzyme (10.000 u/µl or 20.000 u/µL), 2µL of the 
recommended restriction buffer (10X), x µL H2O dest. in order to generate a total amount 
of 20µL.  
 
2.2.4.7 Nucleic Acid Separation and Visualization by Electrophoresis  
 
For visualization of different sized RNA and DNA fragments, nucleic acids were separated 
on a 0.7-1% agarose gel which contained 0.1µg/mL of the fluorescent dye SYBR-Safe. 
Nucleic acids were mixed with 6x gel loading buffer and applied on the gel. Additionally, 
a standard marker was applied to allow size orientation of the fragments. In case that an 
extraction was needed from the gel, the specific band was cut out under UV light and 
cleaned up with the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) according to 
the supplier’s recommendations. Purified DNA was eluted in 30µL of supplied elution 
buffer.  
 
2.2.4.8. Isolation of Genomic DNA  
 
For several applications the isolation of genomic DNA (gDNA) from whole cells was 
affordable. Therefore, the QIAamp DNA Blood Mini Kit was applied. At least approximately 
5 x 106 cells were spun down for five min at 300g and room temperature and then 
resolved in 200µL PBS by gently pipetting up and down.  As recommended in the protocol, 
a 1.5mL tube holding 20µL Proteinase K was prepared and the cells suspension was 
added. This procedure ensures protein digestion for the following nucleic acid extraction.  
For efficient lysis, 200µL of buffer AL were supplemented and the suspension was 
vortexted for 15sec and then incubated for 10min at 56°C in a heat block. All further steps 
were performed as recommended by the supplier. Concentration of gDNA was 
determined by measurement with the Nanodrop machine.  
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2.2.4.9 Isolation of RNA  
 
For RNAseq analysis, isolation of RNA was affordable. This was performed with the 
RNeasy Kit (Qiagen, Hilden, Germany). All pipetting steps were performed with filtered 
tip to decrease the eventual degradation of the RNA. Additionally, the whole work space 
was cleaned with EtOH (70%) and RNase Away solution. The optional DNAse digest step 
was always performed.  
 
2.2.4.10 Multiplex Ligation-dependent Probe Amplification (MLPA) 
 
Multiplex ligation-dependent probe amplification (abbreviated with MLPA (Figure 6)) is 
a method to detect copy number variation and it was applied for examination of different 
patient/PDX samples. The principle of MLPA is based on probes which bind a specific DNA 
sequence of approximately 60nt length. The reaction results in a set of unique PCR 
amplicons between 64–500nt which can be separated through capillary electrophoresis. 
In a multiplex PCR each gDNA sample can be investigated for deletions in a specific gene 
set. The gDNA was denatured and specific hybridization primers (probes) attached to a 
linker sequence bind specific loci. One PCR primer is fluorescently labelled enabling the 
amplicon fragments to be visualized during the fragment separation. Fragment analysis 
was carried out in cooperation with the “Zentrum für Humangenetik und 
Laboratoriumsdiagnostik” (MVZ, Martinsried, Germany). The analysis followed with 
Genemarker V2.6.0 software in order to compare different patients. For all experiments, 
the SALSA MLPA P414 MDS probemix (MRC Holland, Amsterdam, NL) was applied and 
carried out according to the protocol.  
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Figure 6: Multiplex ligation-dependent probe amplification. Stepwise explanation of the MLPA 
procedure, where chromosomal microdeletions can be detected: After DNA denaturation, specific probes 
can bind to distinct regions in the genomic DNA. In a PCR step these regions can be amplified and afterwards 
detected by capillary electrophoresis. Further ratio analysis provides information about genomic deletions.  
 
First, DNA was denatured by heating the sample up to 98°C for five min. Hybridization of 
the probes was performed by adding 3µL of the hybridization mixture after cooling down 
the sample to room temperature. The mixture was incubated at 95°C for one minute and 
hybridization followed for 16h at 60°C. Hereinafter, the cycler’s temperature was 
decreased to 54°C followed by adding 32µL of the ligase mixture. The suspension was 
incubated for 15min at 54°C. To inactivate the ligase, the suspension was heat up to 98°C 
for 15min. For product amplification, the samples were cooled down at room temperature 
first. 10µL of the polymerase master mix induce amplification setup. PCR thermocycler 
program is shown below. For evaluation of the PCR fragments, relative peaks were 
determined in each probe. For evaluation of patient samples, control fragments and 
binning DNA controls (provided in the kit) were used as probe binding controls and cell 
line experiments were used as last control to evaluate EZH2 status.  
2.2.4.11 Digital Droplet PCR (ddPCR) 
 
Digital droplet PCR (ddPCR) is a special PCR method which allows direct quantification 
and amplification of nucleic acid strands. The method is based on water-oil emulsion 
droplet technology which makes it more precise than conditional PCR. One sample is 
fractioned into thousands of droplets and amplification occurs in each individual droplet.  
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This enormous sample partitioning is a key feature of the technique. For ddPCR, a special 
kit was designed (ddPCR MUT FAM/HEX-EZH2/p.A692G) in cooperation with Bio-Rad 
(Hercules, US) for the precise detection of the time point the EZH2 mutation raised in the 
patient. All steps for ddPCR were performed as recommended in the manufacturers’ 
protocol.  
 
2.2.5. Sequencing  
2.2.5.1. Sanger Sequencing 
 
For the validation of correct PCR products and plasmid DNA fragments, sanger 
sequencing was executed external by Sequiserve (Vaterstetten, Germany). Verification of 
correct cloning and site-directed mutagenesis was confirmed for each maxi-preparation 
with full-length sequencing.   
 
2.2.5.2. RNA Sequencing  
Complete RNA sequencing procedure was performed as is was previously described by 
Stief et. al, 2019123. Experiments and data evaluation were done by Sabrina Weser (ELLF, 
Klinikum der Universität München). In short, a modified protocol from the SCRB-seq 
technique was used111. All wetlab and bioinformatic analyses were performed as 
described in Stief et al., 2019123.  
 
2.2.6. Statistical Analysis  
 
Statistical analysis of all assays (proliferation and biochemical assays) was performed 
using GraphPad Prism 6.07 (GraphPad Software (La Jolla, CA, USA)) software.  All 
presented results include the mean ± SD of a minimum of three biological replicates, 
except if indicated otherwise. For biochemical and proliferation assays, the statistical 
significance was calculated by an unpaired, two-tailed t-test. All graphs shown were 
created with GraphPad Prism 6.07 software. The association of EZH2 mRNA expression 
with clinical, genetic and outcome variables was analysed in publicly available data sets. 
Patients of the AMLCG1999 trial were used as discovery cohort (GSE37642)117,118 and 
results were validated in patients intensively treated in trials of the HOVON (Haemato 
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Oncology Foundation for Adults in the Netherlands) group (GSE14468)119,120. Maximally 
selected rank statistics121 were used to dichotomize EZH2 expression in the discovery 
cohort. The identified cut point was independently validated in the HOVON data set. 
KaplanMeier estimates for overall survival (OS) were calculated using the R survival 
package with standard parameters. p-values were calculated using the log-rank test. 
Statistical analysis was performed using the R-3.4.1 software package (R Core Team. R A 
language and Environment for Statistical Computing). 
2.2.7. In vivo Therapy Trial 
 
All trials including animals were performed in conformity with the present ethical 
guidelines of the formal committee on animal experimentation (Regierung Oberbayern, 
Nummer 55.2-1-54-2531-95-2010 and ROB- 55.2Vet-2532.Vet_02-16-7). Patient-derived 
xenograft (PDX) cells were established as it was described previously107. For in vivo 
therapy trials, 1x105 PDX-491 or 8x105 PDX-661 cells were injected intravenously into 
NSG mice (NOD scid gamma, The Jackson Laboratory, Bar Harbour, USA), and tumour 
burden was repeatedly examined by bioluminescence imaging (BLI) as described 
previously107. 21d after transplantation, animals were treated with cytarabine 
(100mg/kg, i.p., days 1-4, 15-18, 29-32, and 43-46) and DaunoXome (1mg/kg, i.v., days 1, 
4, 15, 18, 29, 32, 43, 46). Tumour burden was regularly monitored by BLI.  
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3. Results 
3.1. Recurrent EZH2 Mutations at AML Diagnosis 
 
Figure 7: Recurrent EZH2 mutations at AML diagnosis. a, Schematic illustration of EZH2 protein 
structure (NM_004456.4) and identified mutations (27 in total, c.2195+1G>A appeared twice) in AML 
patients at diagnosis. Presented EZH2 mutations were found in AML-CG-99 trial (NCT00266136) and AML-
CG-2008 trial (NCT01382147). Functional domains are indicated at distinct locations and truncating 
mutations are displayed in red. Asterisks indicate mutations, that were further investigated; b, Histogram 
showing VAF (in %) of detected EZH2 mutation; c, Plot presenting the prognostic subgroups of 25 patients 
with EZH2 mutation according to the ELN classification; d, Survival plot showing overall survival (OS) in 
patients with low or high mRNA EZH2 expression; e, Survival plot showing relapse-free survival (RFS) in 
patients with low or high mRNA EZH2 expression.  
 
c.
Fig. 1. Recurrent EZH2 mutations at diagnosis. a, Schematic overview of EZH2 protein structure
(NM_004456.4) and identified mutations (27 in total, c.2195+1G>A appeared twice) in AML patients at
diagnosis. Presented EZH2 mutations were found in AMLCG-99 trial (NCT00266136) and AMLCG-2008
trial (NCT01382147). Functional domains re indicated at disti ct locations and truncating mutations re
displayed in red. b, Overview of different recurrent driver mutations in AML patients at diagnosis
according to their respective functional group. Data was obtained from Metzeler et al.,2016. c, Plot
prese ting the prognostic subgroups of 25 patients with EZH2 mutation according to the ELN
classification from 2017eln paper d, Survival plot showing overall survival (OS) in patients with low or
high EZH2 expression. e, Survival plot showing relapse-free survival (RFS) in patients with low or high
EZH2 expression. *p<0.05; **p<0.01; ***p<0.001 TEST klären mit Tobias
a.
b.
d. e.
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A few years ago, Metzeler et al. from our department described EZH2 mutations within a 
broad spectrum of driver mutations in AML patients34 in the clinical trials AML-CG-1999 
(NCT00266136, n = 390) and AML-CG-2008 (NCT01382147, n=274). 27 EZH2 mutations 
were detected in 25 AML patients at diagnosis (Figure 7a), referring to a mutation rate of 
4% (n=25/664).  74.07% (n=20/27) of these mutations are located in the SET ([Su(var)3-
9, Enhancer-of-zeste and Trithorax]) or CXC domain (cysteine-rich region, sometimes 
referred to as pre-SET domain) at the C-terminus of the protein, which are responsible 
for the catalytic activity of the methyltransferase. 11 (40.7%) mutations cause a stopgain 
or frameshift leading to a truncated protein. Moreover, 2 (7.4%) frameshift mutations 
result in an elongated protein variant. Most frequently detected additional mutations in 
EZH2 mutated patients are EZH2/RUNX1 (44%, n=11/25), EZH2/ASXL1 (44%, n=11/25), 
EZH2/DNMT3A (20%, n=5/25) and EZH2/TET2 (20%, n=5/25). Interestingly, mutations 
in NPM1 can only be found in 12% (n=3/25) of all patients with EZH2 mutation 
(Supplementary Figure 1a). A wide range of variant allele frequencies (VAF) reaching 
from 2.5%-100% (Figure 7b) was detected.  In order to compare the prognostic relevance 
of EZH2 mutations, EZH2 mutated patients were classified in risk groups, according to the 
ELN classification from 201733. 76% (n=19/25) of EZH2 mutated patients can be assigned 
to an adverse risk category (Figure 7c). To evaluate the impact of EZH2 status on patient 
survival, the survival of individuals with EZH2 mutation in the cohorts which are 
described above were compared. Even though a poor overall survival (OS) for patients 
with monosomy 7 could be confirmed (Supplementary Figure 1b), where EZH2 is located, 
a difference in the OS of patients harbouring EZH2 mutations could not be observed 
(Supplementary Figure 1c). A significant difference could be observed when EZH2 
mutated patients in the adverse risk group were compared to patients with intermediate 
or favourable phenotype but not when EZH2 mutated patients (adverse risk group) are 
compared to the EZH2 wildtype control group (Supplementary Figures 1d-e). Next, 
expression levels in AML patients were compared and the survival of individuals with 
low/high EZH2 expression was compared. Low EZH2 mRNA expression was significantly 
associated with poor relapse free survival (RFS) and OS in publicly available independent 
data sets of the AML-CG (GSE37642, Figure 7d-e) and HOVON (GSE14468, supplementary 
Figure 2b) study groups119,120,122.  
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3.2. EZH2 Expression is Often Altered in AML Patients Between Diagnosis 
and Relapse  
 
 
Figure 8: Relevance of EZH2 status in AML relapse. a, Immunoblotting for EZH2 protein expression in 
10 AML patients123 at diagnosis and relapse. Molecular weight (MW); β-actin: loading control. The ratio of 
EZH2 to β-actin expression is indicated below and presented in the histogram above. Each relapse value 
was normalized to the corresponding diagnosis sample; b, Plot showing EZH2 mRNA expression in 35 CN-
AML patients between diagnosis and relapse; c, Graphs showing VAF (in %) of two EZH2 mutations with 
outgrowth in first/second relapse in AML patients. 
 
 
 
 
 
 
b. c.
Fig. 2. EZH2 in AML relapse. a, Immunoblotting for EZH2 protein expression in 10 AML patients at
diagnosis and relapse. MW, molecular weight; ß-actin, loading control. The ratio of EZH2 to ß-actin
expression is indicated below and presented in the histogram above. Each relapse value was
normalized to the corresponding diagnosis sample. b, Plot showing EZH2 RNA expression in 35 CN
AML patients. c, Graph showing the comparison of variant allele frequencies (VAF) of EZH2 mutations
in 2 AML patients between diagnosis and relapse or second relapse. EZH2/p.A692G and
EZH2/c.2195+1 G>A have both been reported previously in MDS (c.2195+1G>A) and follicular
lymphoma (p.A692G) 2 paper.
a.
 Error! Use the Home tab to apply Überschrift 1 to the text that you want to appear here. 
  - 45 - 
Because a poor RFS was observed in patients with low EZH2 mRNA expression, protein 
expression in a set of relapsed AML patients123 was investigated. In a screening of ten 
patients (Table 15: Patient characteristics from samples shown in Figure 8a), matched 
diagnosis-relapse samples were compared to evaluate the change of EZH2 expression 
during disease progression (Figure 8a-b). In 50% of these patients, decreased levels of 
EZH2 protein expression were observed, whereas 50% revealed increased protein 
expression levels at relapse. A strong decrease of protein expression could be found in 
three patients (UPN#1 - UPN#3), whereas a strong increase of protein expression was 
observed in two patients (UPN#9 and UPN#10). An additional analysis of EZH2 mRNA 
regulation in 35 CN-AML patients resulted in an alteration of EZH2 expression in 74.3% 
(n=26/35) of all relapsed patients. Only 25% (n=9/35) patients did not show any 
significant alteration in EZH2 mRNA levels between diagnosis and relapse (Figure 8b; 
Supplementary Figure 2a). In addition to changes in expression, two relapse-associated 
EZH2 mutations were found in AML-CG study. EZH2/p.A692G could be confirmed in the 
second relapse of a patient and EZH2/c.2195+1G>A in the first relapse of another patient. 
Both mutations revealed subclonal outgrowth during AML treatment and increasing 
variant allele frequencies (VAF) in relapsed AML samples (Figure 8c). 
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Table 15: Patient characteristics from samples shown in  Figure 8 (adapted from Stief et. al, 
2019123 ) 
UPN Age at 
Diagnosis 
 
Sex Karyotype at 
Diagnosis 
Karyotype  
at Relapse 
Time to 
Relapse 
Induction 
Therapy 
#1 76 m CN CN 176 s-HAM 
#2 57 f CN CN 468 TAD9-HAM 
#3 56 f CN CN 2294 sHAM+TAD 
#4 38 f 47,XX,+8[15]//
46,XX[2] 
47,XX,+8[6]/47,sl,t(2;13)
(p21;p11)[2]/47,sl,t(1;13
)(p36;q?3),t(1;20)(q21;?
q13),t(1;8)(q21;q22),t(3;
4)(q2?8;q3?4),t(3;5)(q1?;
q3?5),t(5;9)(q31;p22),t(6
;13)(q2?;q?3),t(9;15)(q3?
4;q1?5)[cp8]//46,XX[2] 
137 sHAM 
#5 33 f NA NA 728 NA 
#6 62 m CN CN 680 sHAM+TAD 
#7 71 m CN 46,XY,t(1;22)(p13;q11),d
er(5)t(5;19)(q12;?),der(1
5)t(5;15)(q?;q?),der(19)t
(15;19)(q?:q?)[5]/46,XY,t
(11;13)(p1?;q1?)[3]/46,X
Y[1] 
209 sHAM 
#8 44 m 47,XY,+21[16]/
46,XY[6] 
46,XY,i(7)(q10),der(9)(p
?),del(9)(p1?)[9] 
860 TAD-HAM 
#9 68 f 47,XX,+8 [25] NA 245 TAD-HAM 
#10 80 m 46,XY,t(2;14)(q
1?;q3?2),del(16
)(q1?3q22)[8].i
shder(2)t(2;14
)(q1?;q3?2)(AL
K+,IGH+),del(1
6)(q1?3q22)(C
BFB,MAF+)/46,
XY [1] 
NA 392 sHAM 
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3.3. Pharmacological Inhibition of EZH2 Induces Sensitivity in MLL-
Rearranged AML Cell Lines  
Figure 9: EZH2 in human AML cell lines. a, Immunoblotting for EZH2 expression and global H3K27me3 
in 11 AML cell lines. Molecular weight (MW); β-actin and H3 total: loading controls. b; Correlation between 
EZH2 protein expression and global H3K27me3 in haematopoietic cell lines (Expression levels normalized 
to HEK293T control; Pearson`s correlation; R2=0.5384, *p=0.024); c, Graphs showing IC50 values of AraC 
treatment in AML EZH2 wildtype cell lines with combinatorial treatment with GSK126 for 72h. Cells were 
first pre-incubated with 1µM GSK126 for 72h and then treated with 1µM GSK126 and AraC for 72h. Mean 
(including s.d) are shown for three biological replicates. Unpaired, two-tailed Student’s t-test; *p<0.05; 
**p<0.01; ***p<0.001; ***p<0.0001. 
Fig. 2. EZH2 in AML relapse. a, Immunoblotting for EZH2 protein expression in 10 AML patients at
diagnosis and relapse. MW, molecular weight; ß-actin, loading control. The ratio of EZH2 to ß-actin
expression is indicated below and presented in the histogram above. Each relapse value was
normalized to the corresponding diagnosis sample. b, Plot showing EZH2 RNA expression in 35 CN
AML patients. c, Graph showing the comparison of variant allele frequencies (VAF) of EZH2 mutations
in 2 AML patients between diagnosis and relapse or second relapse. EZH2/p.A692G and
EZH2/c.2195+1 G>A have both been reported previously in MDS (c.2195+1G>A) and follicular
lymphoma (p.A692G) 2 paper.
b.a.
c.
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Because a difference in protein and mRNA expression patterns of EZH2 in AML patients 
between diagnosis and relapse was found, EZH2 protein expression was evaluated in 
human AML cell lines (Figure 9a). Four cell lines with EZH2 mutation and seven EZH2 
wildtype cell lines were investigated in a protein expression screening.  Two clusters 
could be observed, cell lines with comparatively high expression and cell lines with 
comparatively low expression. A low protein expression was observed in 75% (n=3/4) of 
all mutated cell lines. OCI-AML 5 revealed high expression levels even though EZH2 is 
mutated. This mutation was previously described to show a strong LOF phenotype124, 
which could be confirmed in our screening, since global H3K27me3 levels are completely 
absent. As expected, EZH2 was strongly expressed, whereas methylation of H3K27me3 
was completely absent. Expression was in general stronger in wildtype cell lines with 
exception of the cell line U937. Global H3K27me3 levels were lower in all mutated cell 
lines, which could be confirmed in a linear regression plot (Figure 9b).  
 
In order to evaluate the effect of impaired EZH2 function on drug resistance, human AML 
cell lines were treated with a combination of the highly specific EZH2 inhibitor GSK126 
and the cytostatic drug AraC. A significant decrease in IC50 values could be observed in the 
cell lines MV4-11 and Molm13 (Figure 9c), both characterized by MLL-rearrangements, 
confirmed by DSMZ (Braunschweig, Germany). For two additional EZH2 wildtype cell 
lines (HL-60 and Kasumi1) no alteration in the sensitivity against AraC was observed 
under GSK126 treatment. In summary, pharmacological inhibition of EZH2 by GSK126 
sensitizes against AraC treatment in two MLL-rearranged cell lines.  
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3.4. EZH2 Mutations in AML Patients are LOF Mutations 
  
Figure 10: Evaluation of EZH2 mutations found in AML patients at diagnosis. a, Immunoblotting for 
EZH2 expression and global H3K27me3 in HEK293T sc clones. Molecular weight (MW); β-actin and H3: 
loading controls; b, Correlation between EZH2 expression and global H3K27me3 in HEK293T/ EZH2-/- sc 
clones (Pearson`s correlation; R2=0.975, *p=0.002); c, Immunoblotting for EZH2, SUZ12, RBAP46 and EED 
in HEK293T/EZH2-/- sc clones. Molecular weight (MW); β-actin: loading control; d, Graph showing AraC 
resistance in a HEK293T/EZH2-/- clone. Cells were treated for 72h with AraC. Mean (including s.d.) are 
shown for three biological replicates. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001; 
e, Histogram showing the biochemical H3K27me3 activity of different EZH2 mutations which were detected 
at diagnosis. Colours refer to different protein structures caused by the mutation. Mean (including s.d.) are 
shown for minimum three biological replicates. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; 
***p<0.001; f, Histogram showing the biochemical activity of different EZH2 mutations in the context of 
wildtype background. Mean (including s.d.) are shown for minimum three biological replicates. Unpaired, 
two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001; g, Microscopic imaging of HEK293T sc clones. 
Representative images are shown for each status of zygosity.  
Fig. 3. Evaluation of EZH2 mutations found in AML patients at diagnosis. a, Immunoblotting for
EZH2 expression and H3K27me3 in 6 293T single cell clones. MW, molecular weight; β-actin and H3
total, loading controls. b, Correlation between EZH2 protein expression and global H3K27me3 in 293T
single cell clones (Pearson`s correlation; R2=0.5384, *p=0.024). c, Immunoblotting for EZH2, SUZ12,
RbAP46 and EED expression in 2 293T EZH2 -/- single cell c nes. MW, molecular weight; β-actin,
loading control. d, Graph showing AraC resistance in a 293T EZH2 -/- clone. Cells were treated for 72h
with AraC. Mean  s.d are given for three independent experiments. Unpaired, two-tailed Student’s t-
test; *p<0.05; **p<0.01; ***p<0.001 e, Histogram showing the biochemical H3K27me3 activity of 7
different EZH2 mutations which were detected at diagnosis. Colors refer to different protein structures
caused by the mutation. 293T EZH2 -/- cells were transfected transiently with EZH2 constructs for 72 h
and global H3K27me3 was evaluated by immunoblotting. Mean  s.d are given for minimum three
independent experiments. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001. f,
Histogram showing the bi chemical activity of 4 different EZH2 mutations in the co text of wildtype
background. 293T EZH2 -/- cells were transfected transiently with EZH2 constructs for 72 h with EZH2wt
and EZH2mut constructs. Mean  s.d are given for minimum three independent experiments. Unpaired,
two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001.
c.b.
d. f.e.
a.
EZH2 +/+ EZH2 +/- EZH2 -/-
g.
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In order to evaluate the importance of EZH2 LOF in myeloid malignancies, the biochemical 
activity of mutated EZH2 variants, which were found at diagnosis and relapse, was 
investigated. Therefore, the global H3K27 tri-methylation potential was tested in vitro. 
For this purpose, a HEK293T/EZH2 knockout (KO) model (Figure 10a) was established. 
Therefore, CRISPR/Cas9 mediated genome editing was applied, targeting exon 3 of EZH2. 
Thereby, different clones (homozygous KO (EZH2-/-), heterozygous KO (EZH2+/-) and 
wildtype (EZH2+/+)) could be established. It should be noted, that EZH2 protein 
expression levels strongly correlated with global H3K27me3 levels in HEK293T single cell 
(sc) clones (Figure 10b). Whereas protein expression and global H3K27me3 levels were 
present in EZH2+/+ clones, they were completely absent in all EZH2-/- clones. EZH2+/- 
clones exposed decreased EZH2 expression levels and, compatible, diminished global 
H3K27me3 levels. To evaluate whether endogene loss of EZH2 is leading to a destabilized 
protein complex in HEK293T/EZH2-/- sc clones, the presence of PRC2 components was 
analysed. Expression of all PRC2 components (including SUZ12, RBAP46 and EED) could 
be shown in both HEK293T/EZH2-/- clones (Figure 10c). Interestingly, both homozygous 
KO clones showed an increased resistance against AraC compared to the 293T/EZH2+/+ 
clone (Figure 10d; Supplementary Figure 3a) and a slightly reduced proliferative 
potential (Supplementary Figure 3b). Re-expression of seven different EZH2 variants 
which were found in the studies AML-CG-1999 (NCT00266136, n=390) and AML-CG-
2008 (NCT01382147, n=274) could only partially rescue global H3K27me3 levels 
compared to the re-expressed wildtype protein (Figure 10e). To validate these results, 
the experiment was performed with a known GOF mutation (EZH2/p.Y646N), which is 
well characterized in lymphomas98,99 and a LOF mutation, which was described in MDS 
(EZH2/Y731F122).  We showed, that p.Y646N mediates increasing global H3K27me3 
levels (Supplementary Figure 10c), while p.Y731F has a LOF phenotype (Supplementary 
Figure 3d). Summarized, all seven tested mutations showed decreased global H3K27me3 
levels compared to the wildtype enzyme, referring to a LOF phenotype. Four mutations 
additionally showed dominant-negative characteristics on the wildtype (Figure 10f). 
Interestingly, HEK293T sc clones revealed different phenotypes concerning morphology 
and growth behaviour. Homozygous sc KO clones formed stucked colonies, the formation 
of pseudopodia was reduced and cells were round-shaped (Figure 10g). Of note, this 
phenotype was not observed in a heterozygous background.  
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3.5. EZH2 Depletion is Associated with AraC Resistance in the Myeloid Cell 
Line K562 
 
 
Figure 11: EZH2 depletion is associated with AraC resistance in the myeloid cell line K562. a, Graph 
comparing IC50 values for DNR and AraC in 9 haematopoietic cell lines. Cells were treated with AraC/DNR 
for 72h. Mean are shown for three biological replicates; b, Immunoblotting for EZH2 expression and global 
H3K27me3 in 13 K562 sc clones. Molecular weight (MW); β-actin and H3: loading controls; c, Plot 
comparing AraC IC50 values in in EZH2+/+ (n=6) and EZH2-/- (n=7) clones. Cells were treated with 
AraC/DMSO for 72h. Each clone represents the mean of three biological replicates. Unpaired, two-tailed 
Student’s t-test; *p<0.05; **p<0.01; ***p<0.001; d, Comparison of proliferation potential in EZH2+/+ (n=4) 
and EZH2-/- (n=7) clones for 7d. Medium was changed every 48h. Mean are shown for three biological 
replicates for each clone. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001; e, Long-term 
low dose AraC treatment in in EZH2+/+ (n=3) and EZH2-/- (n=3) clones. Cells were treated with 30nM 
AraC/DMSO for 12d. Mean (including s.d.) are shown for three biological replicates for each clone. Unpaired, 
two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001 
 
Since a drug resistant phenotype was observed in 293T/EZH2-/- cells, we aimed to verify 
these results in a haematopoietic context. Even though diminished global H3K27me3 
levels were detected in all EZH2 mutated cell lines (Figure 9a), no difference in drug 
sensitivity against DNR (daunorubicin) and AraC (Figure 11a) was observed. In order to 
evaluate complete loss of EZH2 in a myeloid system, seven K562/EZH2-/- sc clones were 
established by using CRISPR/Cas9 mediated gene silencing (Figure 11b) and compared 
b.
Fig. 4 Resistance in the myeloid EZH2 knockout cell line K562 . a, Graph comparing IC50 values for
DNR and AraC in 9 hematopoietic cell lines. Cells were treated with AraC/DNR/DMSO for 72 h. Mean
are given for three independent experiments. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01;
***p<0.001. b, Immunoblotting for EZH2 expr ssion and H3K27me3 in 13 K562 single cell clones. MW,
molecular weight; ß-actin and H3 total, loading controls. c, Plot comparing AraC IC50 values in in
EZH2wt (n=6) and EZH2-/- (n=7) clones. Cells were treated with AraC/DMSO for 72 h. Each clone
represents the mean of three independent experiments. Unpaired, two-tailed Student’s t-test; *p<0.05;
**p<0.01; ***p<0.001. d, Comparison of proliferation potential in EZH2wt (n=6) and EZH2-/- (n=7) clones
for 7 days. Medium was ha ged every 48 . Mean are giv n for three independ nt experiments f r
each clone. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001. e, Longterm low dose
AraC treatment in in EZH2wt (n=3) and EZH2-/- (n=3) clones. Cells were treated with 30 nM AraC/DMSO
for 12 days. Cells were splitted and treated every 4 days. Mean s.d are given for three independent
experiments for each clone. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001.
c. d. e.
a.
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to wildtype sc clones concerning the response to AraC and DNR treatment. Notably, a 
difference between K562/EZH2+/+ and K562/EZH2-/- in DNR resistance could not be 
confirmed (Supplementary Figure 4c). Nevertheless, a significant increase of IC50 values 
for AraC in K562/EZH2-/- sc clones when treated for 72h was observed (Figure 11c) and 
Supplementary Figure 4a). Yet, the IC50 values showed a broad range in K562/EZH2-/- sc 
clones. Additionally, a reduced proliferation was observed in K562/EZH2-/- clones 
compared to K562/EZH2+/+ clones (Figure 11d). Taking this into consideration, we 
decided to investigate treatment resistance against AraC in a long-term proliferation 
assay. Therefore, six sc clones were consequently treated for 12d with 30nM AraC. As a 
result, K562/EZH2+/+ clones show a more sensitive phenotype against AraC compared to 
K562/EZH2-/- clones (Figure 11e). Data of each sc clone is additionally shown in 
Supplementary Figure 4b. In summary, CRISPR/Cas9 mediated KO promotes treatment 
resistance against AraC in the myeloid cell line K562.  
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3.6. EZH2 Re-Expression Sensitizes to AraC Treatment in the Myeloid Cell 
Line K562 
 
Even though a significant difference in the resistance against AraC was observed in 
K562/EZH2-/- clones, sc clones revealed to be highly heterogeneous concerning the 
behaviour during AraC treatment. To overcome this effect, a stable doxycycline inducible 
EZH2 re-expression via PB/Transposase was established in K562/EZH2-/- sc clones. 
Thereby, EZH2 re-expression can be induced by doxycycline treatment to native 
expression levels (Figure 12a). EZH2 expression is induced by doxycycline treatment for 
a minimum of 24h and additional selection by puromycin treatment increases positive 
cells (Supplementary Figure 5).   
 
 
Figure 12: Inducible EZH2 re-expression via PB/Transposase system. a; Immunoblotting for EZH2 
expression in two K562 EZH2-/-/PB/EZH2 sc clones. Cells were treated with 1µg/mL doxycycline for 24h. 
Right: EZH2/wildtype. Molecular weight (MW); β-actin: loading control; Left: EZH2/ c.2195+1G>A. 
Molecular Weight (MW); β-actin: loading control; b, Immunoblotting for EZH2 expression and global 
H3K27me3 levels in two K562 EZH2-/-/PB/EZH2 sc clones. Cells were serially treated for 3d with 1µg/mL 
doxycycline. Right: EZH2 wildtype; Left: EZH2/c.2195+1G>A;. Molecular weight (MW); β-actin and H3: 
loading controls. 
 
 
b.
a.
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We decided to establish EZH2/wildtype (AA1-751) as it was expected, that re-expression 
was able to rescue the resistant phenotype of EZH2-/-. Additionally, EZH2/c2195+1G>A 
was established since this relapse-associated mutation appeared twice in the investigated 
cohorts (diagnosis and relapse) and a strong LOF phenotype was observed in the 
biochemical assay (Figure 10e). EZH2/c.2195+1G>A (AA1-737) was previously described  
in MDS103. This frameshift mutation leads to a sequence variation in the  SET domain and 
results in a premature stop codon and loss of the C-terminal part of the protein103. 
Nevertheless, an impaired and dominant negative methylation activity was observed 
while transiently transfected (Figure 10f). Consequently, the effect of c.2195+1G>A on 
AraC resistance was investigated.  
 
First, the catalytic activity in PB/EZH2 sc clones was analysed. Therefore, global 
H3K27me3 levels were examined after doxycycline induction either in EZH2/wildtype 
and EZH2/c.2195+1G>A clones. Serial re-induction with doxycycline every 24h leads to 
stable global H3K27me3 after 72h in EZH2/wildtype clones. Importantly, global 
H3K27me3 cannot be rescued in EZH2/c.2195+1G>A clones (Figure 12b). To estimate the 
value of mutated EZH2 on chemotherapeutic resistance in leukemic cells, PB sc clones 
were studied in a long-term low dose AraC treatment for 12d. It could be confirmed that 
wildtype EZH2 is capable to re-induce sensitivity against AraC (Figure 13c-d, 
Supplementary Figure 6a). As expected, re-expression of EZH2/wildtype restored 
sensitivity to AraC whereas the LOF (c.2195+1G>A) mutation did not (Figure 13a-b, 
Supplementary Figure 6a). To estimate the effect of doxycycline in this assay, two control 
sc clones (one EZH2+/+ and one EZH2-/-) were tested, which were treated with the same 
experimental settings (Figure 13e-f, Supplementary Figure 6b). No significant effects 
were observed in both control sc clones during treatment with doxycycline. 
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Figure 13: EZH2 re-expression sensitizes to AraC treatment in the myeloid cell line K562: Graphs 
showing AraC low dose long-term treatment in PB/EZH2 clones; a-b, two EZH2/ c.2195+1G>A (LOF) sc 
clones; c-d, two EZH2/wildtype sc clones; e-f, two control sc clones (one EZH2+/+ and one EZH2-/-). Cells 
were pre-treated for 3d with doxycycline and then treated with 30nM AraC/DMSO for 12d. Cells were 
splitted and treated every 4d and doxycycline was added every 48h to ensure stable expression of EZH2. 
Mean (including s.d.) are shown for three biological replicates for each clone. Unpaired, two-tailed Student’s 
t-test; *p<0.05; **p<0.01; ***p<0.001 
 
Fig. 5 Conditional EZH2 re-expression in the myeloid cell line K562 via PB. a-b, Immunoblotting for
EZH2 expression and H3K27me3 in 2 PB/EZH2wt and 2 PB/EZH2mut clones in K562 cells. Cells were
treated with 1µg/ml doxycycline every 24 h. MW, molecular weight; ß-actin and H3 total, loading
controls. c-d, Graphs showing AraC low dose longte m reatment in PB/EZH2 clones. Cells were pre-
treated for 3 days with doxycycline and then treated with 30 nM AraC/DMSO for 12 d. Cells were splitted
and treated every 4 days and doxycycline was added every 48 h to ensure stable expression of EZH2.
Mean s.d are given for three independent experiments for each clone. Unpaired, two-tailed Student’s t-
test; *p<0.05; **p<0.01; ***p<0.001
b.
d.
a.
c. d.
f.e.
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3.7. EZH2 Mutation Induces Resistance in a Patient-Derived Xenograft 
(PDX) Model in vivo  
 
To validate the findings of treatment resistance in haematopoietic cell lines which was 
caused by EZH2 loss, a patient-derived xenograft (PDX) model107 was used (Figure 14, 
Establishment of patient-derived xenografts). Here, primary leukemic patient cells are 
engrafted in immune-deficient NSG mice and can be passaged or analysed in vivo as it was 
previously described107.  
 
 
Figure 14: Establishment of patient-derived xenografts. Primary patient samples engraft in immuno-
deficient NSG mice and can be cultured and analysed in vivo. Cells can be harvested and cultured in vitro for 
a few days for further analysis.   
 
A 54-year old AML patient from an AML-CG cohort was identified who gained an EZH2 
mutation (p.A692G) at second relapse. To confirm that the mutation was relapse-
associated, a sensitive digital droplet PCR (ddPCR) assay (customer designed with Bio-
Rad, Hercules, US) for this mutation was established in patient material. The arise of the 
mutation in the second relapse and the absence in earlier stages could be confirmed 
(Figure 15a; see fractional abundance). Furthermore, the patient gained a heterozygous 
7q deletion at first relapse, as analysed by MLPA (Figure 15a; see 7q del status). A 
summary of the patients’ AML course is shown in Figure 15a. Cells of the first (PDX-AML-
491) and second (PDX-AML-661) relapse were serially transplanted into immune-
deficient mice, establishing patient-derived xenograft (PDX) cells107. Furthermore, PDX 
cells were lentivirally transduced for transgenic expression of luciferase, enabling disease 
monitoring in vivo26. Unfortunately, leukaemia cells of initial diagnosis sample did not 
engraft in the model.  
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Figure 15: Resistance in an EZH2 mutated patient-derived xenograft (PDX) model in vivo. a, 
Illustration of the course of an AML patient with two relapses (indicated with dashed lines). 7q deletion was 
confirmed with MLPA, arise of p.A692G mutation was verified by digital droplet PCR. Sampling time points 
for PDX engraftment is indicated below with arrows. Blast count of each sampling time point from bone 
marrow is given above; b, In vivo treatment of PDX xenograft mice. NSG mice were injected with PDX-AML-
491 PDX cells (left) or PDX-AML-661 PDX cells (right) expressing luciferase. 21 days after injection, mice 
were treated with AraC (100 mg/kg) and DaunoXome (1mg/kg) as indicated above. Leukemic burden was 
supervised by bioluminescence imaging. Treated mice are presented in red, control mice in blue; c, Graphs 
showing VAF in % of mutations found in PDX and patient material analysed with NGS. 
b.
Fig. 6 Resistance in an EZH2 mutated patient-derived xenograft (PDX) model. a, Illustration of the
therapy course of an AML patient with two relapses (indicated with dashed lines). 7q del was confirmed
with MLPA, arise f p.A692G mutation was verified by digital droplet PCR. Sampling time points for PDX
engraftment is indicated below with arrows. Blast count of each sampling time point from bone marrow is
given above. b, In vivo treatment of PDX xenograft mice. Days of treatment with AraC and DNR is
indicated at the top. Left side: Engraftment of PDX-R1. Right side: Engraftment of PDX-R2. Leukemic
burden is measured by bioluminescence imaging. Treated mice are presented in red, control mice in
blue.
a.
c.
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EZH2 mutation status was confirmed in established PDX cells by performing next-
generation sequencing (NGS) in patient and PDX cells. EZH2/p.A692G abundance could 
be confirmed in the second relapse of the patient (VAF: 39.2%) with clonal outgrowth in 
PDX-AML-661 cells growing in mice (VAF: 98.8%). Further mutations identified by 
targeted NGS (Figure 15c) included (i) BCOR, DNMT3A, ETV6, PTPN11, and RUNX1, 
where VAF remained stable at all time points analysed, indicating that these alterations 
are present in the founder clone; (ii) a subclonal NRAS mutation that could be found at all 
time points analysed; (iii) a subclonal KRAS mutation that grew out in the PDX cells of 
PDX-AML-491 but was undetectable in PDX-AML-661 cells; (iv) and a subclonal JAK1 
mutation that was detectable in PDX-AML-661 cells.  
 
To analyse if the gain of the EZH2/p.A692G mutation elicits resistance towards 
chemotherapy in vivo, mice engrafted with either EZH2wt PDX-AML-491 cells or 
EZH2/p.A692G PDX-AML-661 cells were treated with a combination of AraC and DNR 
(DaunoXome). Interestingly, tumour burden in EZH2wt PDX-AML-491 bearing animals 
dropped under therapy, with a complete cure of 3 out of 4 animals, whereas treatment of 
EZH2/p.A692G PDX-AML-661 bearing animals showed only a minimal effect in 
comparison to control treated animals (Figure 15b). These data support the in vitro 
findings that LOF mutations of EZH2 lead to chemotherapy resistance. 
 
 
3.8. Knockdown of EZH2 Promotes Drug Resistance in Patient-Derived 
Xenograft (PDX) Model in vitro  
 
To validate the connection between EZH2 mutation and therapy resistance, PDX-cells 
were screened for AraC response in vitro, and a resistant phenotype of PDX-AML-661 
compared to PDX-AML-491 was confirmed (Figure 16a). Moreover, global H3K37me3 
levels were completely depleted in PDX-AML-661 cells, while EZH2 protein expression 
was stable (Figure 16b). In order to further confirm a LOF phenotype, EZH2/p.A692G was 
transiently expressed in the 293T/EZH2-/- model with the result, that global H3K27me3 
levels were decreased compared to wildtype EZH2 (Figure 16c). Because loss of 
functional EZH2 seems to be of high importance, a siRNA knockdown (kd) targeting EZH2 
in PDX-AML-491 cells was established. EZH2 levels can thereby be reduced to 
approximately 20% of the native levels (Figure 16d). In order to evaluate the behaviour 
 Error! Use the Home tab to apply Überschrift 1 to the text that you want to appear here. 
  - 59 - 
against chemotherapy, cells were treated for 72h with AraC, where a slower proliferation 
(Figure 16e) and an increased resistance (Figure 16f) in EZH2 kd cells compared to 
control-siRNA transfected cells was observed. 
   
 
Figure 16: Knockdown of EZH2 in a patient-derived xenograft (PDX) model in vitro. a, Plot comparing 
IC50 AraC values for PDX-AML-491 and PDX-AML-661 in vitro. Mean (including s.d.) are shown for minimum 
four biological replicates. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001; b, 
Immunoblotting of EZH2 expression and global H3K27me3 in PDX-AML-491 and PDX-AML-661. Molecular 
weight (MW); β-actin and H3 total: loading controls; c, Plot presenting the biochemical H3K27me3 activity 
of EZH2/p.A692G. Mean are shown for five biological replicates. Unpaired, two-tailed Student’s t-test; 
*p<0.05; **p<0.01; ***p<0.001; d, Immunoblotting of EZH2 expression in PDX-AMAL-491 cells treated with 
10nM siRNA. Molecular weight (MW); β-actin: loading control. Representative blot shown for two biological 
replicates; e, Histogram showing the proliferation of PDX-AML-491 cells with 10nM siRNA. Cells were pre-
treated for 2 days with siRNA and then incubated for another 3 days for the proliferation assay. Mean 
(including s.d.) are shown for two biological replicates; f, Graph showing AraC treatment in PDX-AML-491 
cells with 10nM siRNA. Cells were pre-treated for 2 days with siRNA and then treated for 72h with AraC. 
Mean (including s.d.) are shown for two biological replicates. Unpaired, two-tailed Student’s t-test; *p<0.05; 
**p<0.01; ***p<0.001 
 
 
 
 
Fig. 7 Resistance in an EZH2 mutated patient-derived xenograft (PDX) model. a, Plot comparing
IC50 AraC values for PDX-R1 and PDX-R2 in vitro. Mean are given for minimum 4 independent
experiments. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001. b, Immunoblotting of
EZH2 expression and H3K27me3 in PDX-R1 and PDX-R2. MW, molecular weight; ß-actin and H3 total,
loading controls c, Plot showing the biochemical H3K27me3 activity of EZH2/p.A692G in HEK293T
EZH2 -/- cells. Mean are given for five independent experiments. Unpaired, two-tailed Student’s t-test;
*p<0.05; **p<0.01; ***p<0.001. d, Immunoblotting of EZH2 expression in PDX-R1 cells treated with 10
nM siRNA. MW, molecular weight; ß-actin, loading control. Representative blot shown for two
independent experiments. e, Histogram showing the proliferation of PDX-R1 cells with 10 nM siRNA.
Cells were pre-treated for 2 days with siRNA and then incubated for another 3 days for the proliferation
assay. Mean s.d are given for two independent experiments. f, Graph showing AraC treatment in PDX-
R1 cells with 10 nM siRNA. Cells were pre-treated for 2 days with siRNA and then treated for 72 h with
AraC. M an s.d are given for two independent experiments. Unpaired, two-tailed Student’s t-test;
*p<0.05; **p<0.01; ***p<0.001
b.
d. f.
c.
e.
a.
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4. Discussion 
 
Clinical observations and functional data in relapsed AML have shown that loss of EZH2 
expression might contribute to drug resistance.  EZH2 mutations were examined using 
different biological approaches applying patient material, patient-derived xenograft 
(PDX) models (in vitro and in vivo), human AML cell lines and clinical data. The aim of this 
work was to investigate the functional and prognostic impact of mutations in the 
methyltransferase EZH2 in AML. It was hypothesized that functional loss of EZH2 is 
associated with resistance to treatment with chemotherapeutic agents in patients 
suffering from AML. We showed, that EZH2 mutations found in AML patients are loss of 
function (LOF) mutations and that functional inactivation of EZH2 is associated with 
resistance to the chemotherapeutic drug AraC. 
 
4.1. Importance of EZH2 Mutations for AML Patients  
 
In a patient cohort of 664 AML patients23, EZH2 mutations were found in approximately 
4%. Regarding those mutations, a wide variety of variant allele frequencies (VAF) were 
detected, ranging from 2.5% - 100%. More than 74% of the detected mutations in this 
cohort can be found in the catalytic SET domain at the C-terminal portion of the protein. 
Approximately 41% of EZH2 mutations cause structural aberrations, some are truncating 
and a few cause an elongated protein variant due to frameshift mutations. Even though 
76% of AML patients with EZH2 mutation can be assigned to an adverse phenotype, 
increased mortality was not observed for these patients, even though this was recently 
shown for another cohort106. One explanation may be that our small sample size was 
insufficiently powered to detect a survival difference as compared with the larger cohort 
studied by Basheer et al106.  
 
In this work, it was observed that EZH2 mutations frequently occur in patients with 
concurrent RUNX1, ASXL1, TET2 or DNMT3A mutations.  In a 2017 paper, Ernst et al. 
reported that EZH2 mutations in patients with myeloid disorders frequently co-occur 
with TET2 (58%), RUNX1 (40%) and ASXL1 (34%) mutations102. Additionally, EZH2 was 
found to be most frequently mutated simultaneously with RUNX1 and ASXL1 in 
myelodysplastic and myeloproliferative neoplasm, as previously described125. The results 
of this work confirm these observations, since the same mutation pattern was observed 
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in the examined cohort. Additionally, a 2018 study reports that combined Ezh2 and Runx1 
mutations initiate lympho-myeloid leukaemia in early thymic progenitors. Notably, the 
authors report that therapy-resistant leukaemia was associated with the frequent co-
occurrence of EZH2 and RUNX1 inactivating mutations126. In this work, an increased 
mortality was not detected in patients with EZH2 and RUNX1 mutation as compared to 
the control group.   
 
4.2. EZH2 Mutations in AML Patients Are LOF Mutations  
 
The catalytic EZH2 SET domain has been shown to be a hot spot for mutations in several 
cancers including lymphomas and other myeloid malignancies like MDS102–104.   Although 
inactivating mutations of EZH2 are described in MDS, little is known about the impact of 
EZH2 mutations in patients suffering from AML. Even though 74% of all EZH2 mutations 
were found to be located in the SET domain, this work detected several mutations that 
are located N-terminal from the catalytic domains. In order to evaluate the importance of 
EZH2 mutations in AML patients, different patient associated mutations were investigated 
to assess their methyltransferase activity. Thereby, a biochemical assay was established 
to evaluate the potential of EZH2 variants (Figure 17) to maintain global H3K27me3 
levels.  
 
Figure 17: Illustration of investigated EZH2 mutations: Illustration indicates structural aberrations 
which are caused by point or frameshift mutations. 
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Transient expression of patient associated EZH2 mutations in 293T/EZH2-/- cells resulted 
in different global H3K27me3 levels detectable by immunoblotting. Previously described 
LOF and GOF mutations were used as controls, revealing diminished or hyper- 
trimethylation levels at H3K27 compared to the wildtype control. Seven different EZH2 
mutations were chosen, which have been found in patients in the cohorts studied. These 
include point mutations or different impacts on the natural protein structure, such as 
truncating or extending mutations. In some patients, mutations that lead to a complete 
loss of the C-terminal part of EZH2 were found. One mutation (EZH2/p.Q610X) was 
chosen to analyse a representative mutation lacking the entire SET domain. As expected, 
H3K27me3 levels were completely absent when these mutations were expressed.  
 
Furthermore, one variant with a premature stop codon at p.Y730 was investigated 
(EZH2/p.D730_731DelinsX), found in one patient. This resulted in a strong decrease in 
measured global H3K27me3 levels, as expected, considering that Y731 of EZH2 is highly 
conserved and also essential for the SAM cofactor binding site127,127. These findings support 
the hypothesis that the C-terminal portion of the SET domain is essential for maintaining 
global H3K27me3 levels. EZH2/c.2195+1G>A (Y733LfsX6) was previously described in 
2010 in MDS103. This mutation causes an alternate sequence in the SET domain and the 
absence of the C-terminal portion of the enzyme. This was of critical importance for the 
methylation activity of EZH2, since global H3K27me3 levels are completely abolished 
when this mutation was re-expressed.  
 
In summary, the C-terminal part of the SET domain was indispensable for the catalytic 
activity of the enzyme. Nevertheless, the point mutations EZH2/p.K574E and 
EZH2/p.D293G revealed impaired catalytic activity with EZH2/p.K574E showing the 
most severe impact on global H3K27me3 in our experimental settings. Missense 
mutations at residues coordinating the first and second zinc ion of the CXC domain were 
reported in AML (p.H525N) and in MDS (p.C571N). This suggests that a disruption of the 
CXC domain of EZH2 also has a strong impact on the catalytic activity of the 
methyltransferase102,128. It was shown that EZH2 CXC domain is involved in the 
nucleosome interaction and that mutations  in this region perturbate proper binding of 
the histone tail129. We therefore hypothesize, that histone tail interaction is impaired by 
p.K574E, whereby H3K27 cannot be methylated due to abrogated H3 tail binding.  
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In this work, LOF phenotypes were also detected in frameshift mutations, which cause an 
elongated transcript variant. EZH2/p.I744fs has been previously described in AML130,130, 
but without further information concerning the biochemical activity. EZH2/p.G743fs and 
p.I744fs both have impaired catalytic activity, even though the SET domain sequence is 
unchanged. This leads to the conclusion that, not only a correct protein sequence is 
necessary for methyltransferase activity, but also the steric integrity of the C-terminal 
part is highly critical for the functionality of the EZH2. Changes causing an elongated 
protein might influence the interaction with PRC2 members or induce steric hindrance 
within the enzymatic reaction.  
 
In summary, EZH2 LOF mutations seem to play an important role in the pathogenesis and 
progression of AML. As expected, different AML-related mutations were found to be 
determined as LOF mutations, both truncating and non-truncating mutations. Catalytic 
loss of H3K27me3 by EZH2 mutations support the hypothesis that the functional activity 
of EZH2 plays a relevant role in these AML patients. Additionally, a dominant negative 
effect in 50% of all tested mutation was observed, highlighting the importance of a 
heterozygous mutation status.  Since EZH2 mutations most frequently occurred in a 
heterozygous background in our cohorts this fact is of importance. We therefore 
hypothesize that also a heterozygous mutation status is also sufficient to induce loss of 
H3K27 methylation and thereby cause drug resistance in a subset of patients.  
 
4.3. Loss of EZH2 Expression is Associated with Poor Survival  
 
In this work, EZH2 mRNA expression levels were shown to be altered in more than 70% 
of matched diagnosis-relapse pairs of AML patients. Additional analysis of protein 
expression levels revealed both increasing and decreasing levels of EZH2 expression in 
relapsed patients. Overall, EZH2 decrease was observed in 23-50% of relapsed patient 
samples.  
In a 2016 publication, Göllner et al. reported altered EZH2 protein levels in AML 
patients131. In that study, a decrease of EZH2 protein and global H3K27me3 levels was 
detected in 45% of relapsed samples in matched diagnosis-relapse pairs. The results of 
that work are consistent with our findings since a decreased expression of EZH2 was 
found in 23-50% of AML patients by analyzing mRNA and protein expression levels. It 
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was also shown by Göllner et al. in a cohort of 124 patients, that low expression levels of 
EZH2 correlate with a poor prognosis. The results shown here confirm that generally low 
EZH2 expression correlates with a poor OS and a poor RFS in AML patients. In addition to 
low expression levels, two relapse-associated EZH2 mutations were detected in patients, 
which show clonal outgrowth in AML relapse. EZH2/c.2195+1G>A (Y733LfsX6) and 
EZH2/p.A692G are both located in the SET domain and were observed in a first and a 
second relapse of two patients. We therefore hypothesize, that in addition to protein loss, 
EZH2 mutations might also play an important role in the development of drug resistance 
in AML.  
 
4.4. Loss of EZH2 is Associated with Chemotherapeutic Drug Resistance 
and Provides Selective Advantage in Relapsed AML Patients 
 
Loss of EZH2 expression was shown to be associated with treatment resistance in AML 
patients by Göllner et al. in 2016. They proposed that proteasomal degradation of the 
EZH2 protein results in chemotherapeutic resistance by de-repression of downstream 
EZH2  target genes such as HOXA9 and HOXB8131. Göllner et al. further found that loss of 
EZH2 induces resistance against standard chemotherapeutic drugs such as AraC and 
tyrosine kinase inhibitors (Midostaurin), which results from degradation of the EZH2 
protein. They showed that application of proteasome inhibitors was able to rescue the 
sensitivity in AML cell lines and patient samples131. At the genetic level, loss of 
chromosome 7 or partial deletions such as 7q deletions are common in AML patients and 
have been shown to be an adverse prognostic factor (ELN classification from 201733). 
Since EZH2 is located on 7q36, partial loss of chromosome 7 or the q arm of chromosome 
7 directly impacts EZH2 protein expression.  
 
In this work, two EZH2-/- cell lines were established by using CRISPR/Cas9 genome editing 
in order to evaluate resistance towards cytotoxic agents in cells lacking EZH2 expression. 
We could show that complete loss of EZH2 results in a resistance against AraC in 
HEK293T cells and in the myeloid cell line K562. These data are therefore supportive of 
the previous work from Göllner et al. The findings were extended with respect to EZH2 
mutations which are recurrently found in AML and MDS patients, by showing that re-
expression of wildtype EZH2, but not EZH2 LOF mutations restore sensitivity, showing 
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that the catalytic activity might influence chemotherapeutic drug resistance. In order to 
confirm whether EZH2 mutation status might also drive resistance mechanisms in AML 
patients, an inducible EZH2 mutated model was established in this work. It was shown 
that wildtype EZH2 was able to re-induce sensitivity in EZH2-/- cells, but LOF mutation, 
where global H3K27me3 was completely lost, did not. It is therefore assumed that loss of 
the catalytic activity of EZH2 plays a major role in a resistance mechanism in AML 
patients. 
 
To extend these results to an in vivo system, a patient-derived xenograft (PDX) model was 
used107, which uses patient-derived primary leukaemia cells that engraft in immuno-
deficient NSG mice. Matched patient samples from a first (PDX-AML-491) and second 
(PDX-AML-491) relapse of an AML patient were compared, where EZH2 is mutated 
(EZH2/p.A692G) in the second relapse. Importantly, this mutation shows subclonal 
outgrowth to up to 98.8% VAF in vivo in mice, suggesting that the mutation is selected by 
a clonal evolution process during tumour development. We hypothesize that functional 
inactivation of EZH2 drives mechanisms allowing the resistant clone to grow within the 
tumour mass.  Loss of EZH2 provides a selective growth advantage, which might be 
explained by an increased resistance to chemotherapeutic drugs since drug resistance 
could be detected in the EZH2 mutated relapsed PDX (PDX-AML-661) both in vivo and in 
vitro. In these cells, global H3K27me3 levels were strongly reduced, indicating a LOF 
phenotype of the mutation which was confirmed in an additional biochemical assay.  
 
Interestingly, EZH2/p.A692 was previously described as a mutational hot spot that occurs 
in lymphoma patients99. A similar mutation (p.A692V) was formerly characterized as a 
GOF mutation in a heterozygous background132. In this work, the mutation was detected 
in a hemizygous background, since an additional deletion of 7q was present in this patient. 
It has been known for years that EZH2 GOF mutations in lymphomas require a wildtype 
EZH2 (heterozygous background) to induce a hyper-trimethylation phenotype101. Thus, 
wildtype and mutant alleles collaborate to elevate H3K27 methylation, highlighting the 
importance of the heterozygous status. The experimental setting of our PDX model has 
limitations since additional mutations co-occur in the second relapse of the patient (PDX-
AML-661), which could be verified by NGS. To overcome these restrictions, a knockdown 
of EZH2 in PDX-AML-491 cells was established to investigate EZH2 dependence in vitro. 
It was shown that downregulation of EZH2 is responsible for the drug resistant phenotype 
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in vitro, supporting the hypothesis that loss or functional inactivation of EZH2 directly 
induce chemotherapy resistance in AML. 
4.5. Downstream Effects of Genetic De-Repression Caused by EZH2 Loss 
 
Since EZH2 mutations are rare events in AML, more clinical studies are necessary to 
address the importance of EZH2 mutations and expression status in order to evaluate the 
prognostic relevance of its up or downregulation. Even though EZH2-dependent 
resistance could be confirmed in different models, the origin of drug resistance which is 
dependent on the presence of EZH2 remains unclear. EZH2, a transcriptional repressor, 
is responsible for the suppression of thousands of genes. This requires further 
investigation in order to completely understand how loss of the catalytic activity might 
promote chemotherapy resistance in AML patients.  
 
It has been shown, that repressive marks which are mediated by EZH2 lead to silencing 
of HOX gene clusters131,133. HOX gene clusters encode a huge variety of highly conserved 
transcription factors, which regulate cellular fate during embryogenesis. It is therefore 
generally accepted that homozygous Ezh2 KO is lethal in early stages of mouse 
development134. Generally, HOX gene expression decreases during haematopoietic cell 
maturation135. During haematopoiesis, HOX genes are expressed in lineage- and stage-
specific combinations which are tightly regulated. It has been shown, that overexpression 
of HOXA5 causes an increase in the amount of myeloid progenitors and stopped 
erythroid differentiation136. Another study revealed that upregulation of HOXA10 in 
CD34+ haematopoietic progenitors leads to a significant assembly of blast cells and 
myelopoiesis in parallel with a total block of erythroid differentiation137.  
 
HOXA9 is the most frequently expressed HOX gene in human CD34+ HSCs and early 
haematopoietic progenitors and it is consequently downregulated during cell 
differentiation139.  Hoxa9 overexpression was shown to boost the growth of HSC and 
myeloid progenitor cell proliferation and linked to the induction of leukaemia138. As 
stated atop, HOXA9 is a key controller of haematopoietic programs and it acts as 
oncogene in leukaemia, driving leukemogenesis139. It is comprehensible that HOXA9 
initiates the transcription of genes, which control cell proliferation and survival. 
Consequently, myeloid differentiation is stopped and proliferation is enhanced140. 
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HOXA9 upregulation by EZH2 loss and association with chemotherapeutic resistance 
has also been described by Göllner et al. in 2016. They additionally showed, that 
knockdown of HOXA9 was able to restore sensitivity against TKIs and AraC131. The 
complex network of HOX genes and the fact that there is a wide range of oncogenes and 
tumour suppressors that are targeted by EZH2 (some even independent on the 
trimethylation of H3K27) uncovers the necessity to investigate EZH2 downstream 
mechanisms in more detail.  
Additionally, inhibition of EZH2 and subsequent loss of H3K27me3 has been shown to 
induce cell cycle arrest106 and lower proliferation rates in different cancer associated cell 
models141. One study showed, that depletion of EZH2 leads to DNA damage repair and 
induction of cell senescense142. In that study, the loss of H3K27me3 marks led to 
upregulation of p16 (CDKN2A), which induces DNA repair.  
 
In this work, impaired proliferation was observed in both EZH2-/- cell line models and in 
an EZH2 mutated (LOF) PDX sample. In addition to HOX genes, another set of genes that 
are relevant for cell cycle processes and differentiation are known targets of EZH2. Among 
these, major targets are the Ink4b/Arf/Ink4a loci (encoding the tumour supressors 
p15INK4b, p16INK4a and p14ARF proteins). Inhibition of these genes promotes cell 
proliferation143–145. Hence, de-repression which is caused by EZH2 loss of these targets, 
impairs normal cell proliferation by the induction of cell cycle arrest and apoptosis146. 
EGR1 is another key transcription factor that is directly affected by EZH2 loss. The zink 
finger transcription factor EGR1 (encoded by the EGR-1 (Early growth response protein 
1) gene) is a key transcription factor which mediates important differentiation 
processes147,148. It was found that de-repression and subsequent overexpression of EGR-
1 caused by EZH2 loss promoted differentiation and profoundly diminished AML cell 
growth149. Even though decelerated cell proliferation is not a hallmark of cancers, this 
phenotype might also promote decelerated uptake of chemotherapeutic drugs, such as 
AraC, since their uptake is cell-cycle dependent. 
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4.6. EZH2 Might Act as Tumour Suppressor and Oncogene – Depending on 
the Cellular Context 
 
Many studies within the last years describe EZH2 (or PRC2 in general) in the context of 
an oncogene. This concept is related to the fact that EZH2 overexpression promotes the 
repression of tumour suppressor genes by repressive H3K27me3 marks. In contrast, a 
few years ago an association between EZH2 loss and tumour development was observed 
in pancreatic cancer. In that study, EZH2 loss led to a 6-fold increase in the development 
of pancreatic intraepithelial neoplasia, suggesting a protective role of EZH2 in the 
carcinogenesis of pancreatic cancer150.  
 
The results of this work highlight a tumour suppressor role of EZH2 in AML. Nevertheless, 
high expression levels of EZH2 have been previously found in AML patient samples151 and 
inhibition of EZH2 has been shown to exert anti-leukemic effects in MLL-rearranged 
leukaemias105, as verified for two AML cell lines in this work. It was also reported that 
simultaneous inhibition of the histone demethylase LSD1 and EZH2 was synergistic for 
anti-leukemic activity in AML152. Moreover, recent reports show that concordant 
inhibition of EZH1 and EZH2 has anti-leukemic effects. Specifically, combination therapy 
with both inhibitors reduced the number of LSCs, impaired leukaemia progression and 
prolonged survival times in mouse models153. Additionally, it has been reported that loss 
of EZH2 promotes MDS development, but prevents transformation from MDS to AML in 
MDS mouse models154. These results support an oncogenic role of EZH2 in context of AML. 
 
A novel mouse study showed opposite roles of  the methyltransferase EZH2 in initiation 
and maintenance of AML, suggesting that expression of EZH2 is highly dependent on the 
disease stage106. In that work, stage-specific and entirely opposite roles for Ezh2 at the 
initial and advanced stages of AML were described106. Basheer et al. found that Ezh2 
exerts an oncogenic function in AML maintenance that can be targeted therapeutically in 
patients. Conversely, Ezh2 can also act as a tumour suppressor during disease induction. 
They found the oncogene PLAG1 to be de-repressed by EZH2 loss. This gene is also 
involved in cell cycle programs by affecting the activity of cycle-related genes such 
as Cyclin D3 and Cyclin D1, as well as genes, that are linked to apoptosis, such as Caspase-
8,155 associated with AML induction156.  
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In summary, the results of this work demonstrate that functional loss of the 
methyltransferase EZH2 is associated with a drug resistant phenotype in AML. On the 
other hand, increasing EZH2 expression levels were also observed in more than 50% of 
patients in matched diagnosis-relapse samples, which might lead to the assumption that 
diverse subgroups of EZH2 mutated patients might benefit from different treatment 
recommendations, guided by their EZH2 status. Treatment with small-molecule 
inhibitors has been shown to provide promising results in the treatment of EZH2 mutated 
lymphoma (NCT02082977, NCT01897571) also in addition to AML patients105,153. 
Despite the useful potential of EZH2 inhibitors, further study is needed to address their 
target specificity.  In this thesis, EZH2 inhibitors induce sensitivity towards the 
chemotherapeutic drug AraC in two MLL-rearranged leukaemia cell lines. Nevertheless, 
there is also evidence, that lacking activity of EZH2 also drives resistance mechanisms in 
leukaemia cells. The data presented in this work therefore counsels caution in the 
treatment of AML patients with EZH2 inhibitors, since this might promote 
chemotherapeutic resistance in a subgroup of patients.  
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5. Annex 
5.1. Supplementary Material 
Supplementary Figures  
 
Supplementary Figure 1, related to Figure 7: Recurrent EZH2 mutations at diagnosis. a, 
Illustration of mutation pattern in 25 AML patients at diagnosis. Classification was performed in 
consideration of ELN 2017. Status includes also multiple mutations in one patient. b-e, Overall survival 
plots of patients with monosomy 7 (b), patients with EZH2 mutation (c), patients with EZH2 mutation 
and an adverse phenotype (d) and a comparison of patients with EZH2 mutation and adverse or 
favourable/intermediate phenotype (e).   
Supplementary Fig. 2, related to Fig. 2 Recurrent EZH2 mutations at diagnosis a, Illustration of
mutation pattern in 25 AML patients at diagnosis. Classification was performed in consideration of ELN
2017 paper. Status includes also multiple mutations i one patient. b-e, Overall survival plots of patients
with monosomy 7 (b), patients with EZH2 mutation (c), patients with EZH2 mutation and an adverse
phenotype (d) and a comparison of patients with EZH2 mutation and adverse or favourable/intermediate
phenotype (e). TEST??? *p<0.05; **p<0.01; ***p<0.001.
c. e.d.
b.a.
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Supplementary Figure 2, related to Figure 8: Relevance of EZH2 in AML relapse. a, EZH2 mRNA 
expression levels of 35 CN-AML patients between diagnosis and relapse. b, OS in patients with low/high 
EZH2 expression; HOVON cohort.  
 
 
 
 
 
 
Supplementary Fig. 1, related to Fig. 1. EZH2 in AML relapse. a, Table showing additional
patient information to immunoblotting for EZH2 expression in 10 AML patients at diagnosis and
relapse.
a.
b.
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Supplementary Figure 3, related to Figure 10: Evaluation of EZH2 mutations found in AML 
patients at diagnosis. a, Graph showing AraC resistance in one 293T/EZH2-/- sc clone. Mean (including 
s.d.) are shown for three biological replicates. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; 
***p<0.001. b, Plot showing the colony formation of 3 293T sc clones. Mean (including s.d.) are shown 
for 6 biological replicates. c, Plot showing the biochemical H3K27me3 activity of EZH2/p.Y646N which 
was previously described99. Mean (including s.d.) are shown for four biological replicates. EZH2 
expression was confirmed in the same experimental setting and the ratio of ß-actin and EZH2 is shown 
below. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001. d, Plot showing the 
biochemical H3K27me3 activity of EZH2/p.Y731F which was previously described122. Mean (including 
s.d.) are shown for three biological replicates. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; 
***p<0.001.  
 
 
 
 
Supplementary Fig. 3, related to Fig. 3. Evaluation of EZH2 mutations found in AML patients at
diagnosis. a, Graph showing AraC resistance in one HEK293T EZH2-/- single cell clone. ean s.d are
given for 3 independent experiments. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01;
***p<0.001. b, Plot showing the colony formation of 3 HEK293T single cell clones. Mean s.d are given
for 6 independent experiments. c, Plot showing the biochemical H3K27me3 activity of EZH2/p.Y646N
which was previously described Paper bödöer. Mean s.d are given for four independent experiments.
EZH2 expression w s confirmed in the sam experi ental setting and the ratio of ß-actin and EZH2 is
shown below. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001. d, Plot showing the
biochemical H3K27me3 activity of EZH2/p.Y731F which was previously described Paper... Mean s.d
are give for three ind pe dent exp riments. Unpair d, two-tailed Student’s t-test; *p<0.05; **p<0.01;
***p<0.001.
a.
c. d.
b.
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Supplementary Figure 4, related to Figure 11: EZH2 depletion is associated with AraC resistance 
in the myeloid cell line K562. a, Plot comparing AraC IC50 values in EZH2wt (n=6) and EZH2-/- (n=7) 
clones. Mean (including s.d.) are shown for three biological replicates for each clone. b, Long-term low 
dose AraC treatment in EZH2wt (n=3) and EZH2-/- (n=3) clones. Cells were treated with 30nM AraC/DMSO 
for 12d. Cells were splitted and treated every 4d. Mean (including s.d.) are shown for three biological 
replicates for each clone; c, Plot showing DNR IC50 values for EZH2wt (n=4) and EZH2-/- (n=7) sc clones. 
Cells were treated with DNR/DMSO for 72h. Each clone represents the mean of three biological 
replicates. 
 
 
 
 
 
 
a.
Supplementary Fig. 4, related to Fig. 4 Resistance in the myeloid EZH2 knockout cell line K562. 4.
a, Correlation between EZH2 protein expression and global H3K27me3 9 hematopoietic cell lines
(Pearson`s correlation; R2=0.5384, *p=0.024). b, Plot showing DNR IC50 values for EZH2wt (n=6) and
EZH2-/- (n=7) single cell clones. Cells were treated with DNR/DMSO for 72 h. Each clone represents the
mean of three independent experiments. c, Plot comparing AraC IC50 values in in EZH2wt (n=6) and
EZH2-/- (n=7) clones. Mean are given for three independent experiments for each clone. d, Longterm low
dose AraC treatment in in EZH2wt (n=3) and EZH2-/- (n=3) clones. Cells were treated with 30 nM
AraC/DMSO for 12 days. Cells were splitted and treated every 4 days. Mean s.d are given for three
independent experiments for each clone. e, Schematic representation of exon 3 sequencing for
CRISPR/Cas9 screening. Exon 3 was amplified and sequenced by Sanger sequencing. Exemplary
sequencing of EZH2w shown above, EZH2-/- below.
Name DSMZ no:
K562 ACC-10
293T ACC 635
HL-60 ACC 3
KG1a ACC 421
Molm 13 ACC 554
MV4-11 ACC 102
Oci AML 3 ACC 582
Oci AML 5 ACC 247
PL-21 ACC 536
SKM-1 ACC 547
THP-1 ACC 16
c.b.
Supplementary Table 1 
EZH“ mut!  
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Supplementary Figure 5, related to Figure 12: Inducible EZH2 re-expression via PB/Transposase 
system; here shown in HEK293T cells. Transient co-expression of PB/EZH2 and transposase induces 
stable integration of EZH2 into the genome, accompanied by a fluorescent marker to visualize positive 
expression after doxycycline treatment. Additionally, integrated puromycin resistance offers the 
possibility to select positive cells. Cells were transiently transfected with both vectors (PB/EZH2 and 
Transposase) for 24h. Immediately after transfection, 1µg/ml doxycycline was added. Selection via 
puromycin (2µg/ml) followed 48h later for 7d. K562 clones were sc sorted.  
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Supplementary Figure 6, related to Figure 13: EZH2 re-expression in the myeloid cell line K562 
via PB. a-b Graphs showing AraC low dose long-term treatment in K562 sc clones. Cells were pre-treated 
for 3d with doxycycline and then treated with 30nM AraC/DMSO for 12d. Cells were splitted and treated 
every 4d and doxycycline was added every 48h to ensure stable expression of EZH2 (a, PB/EZH2; b, ctrl 
clones). Mean (including s.d.) are shown for three biological replicates for each clone.  
 
  
Supplementary Fig. 5, related to Fig. 5 Conditional EZH2 re-expression in the myeloid cell line
K562 via PB. a, Immunoblotting for EZH2 expression and global H3K27me3 in 13 K562 single cell
clones. MW, molecular weight; ß-actin and H3 total, loading controls. b, Correlation between EZH2
protein expression and global H3K27me3 in 13 K562 single cell clones (Pearson`s correlation; R2=0.98,
***p=0.0002). c, Graphs showing . Mean are given for three independent experiments. Unpaired, two-
tailed Student’s t-test; *p<0.05; **p<0.01; ***p<0.001. d, Comparison of proliferation potential in in
EZH2wt (n=6) and EZH2-/- (n=7) clones over 7 days. Medium was changed every 48 h. Mean s.d are
given for three independent experiments for each clone. Unpaired, two-tailed Student’s t-test; *p<0.05;
**p<0.01; ***p<0.001. e, Longterm low dose AraC treatment in in EZH2wt (n=3) and EZH2-/- (n=3) clones.
Cells were treated with 30 nM AraC/DMSO for 12 days. Cells were splitted every 96h. an are given for
three independent experiments for each clone. Unpaired, two-tailed Student’s t-test; *p<0.05; **p<0.01;
***p<0.001
a.
b.
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5.3. Single Letter Codes for Amino Acids  
 
Single letter code Amino Acid  
nonpolar  
A Alanine (Ala) 
V Valine (Val) 
L Leucine (Leu) 
I Isoleucine (Ile) 
M Methionine (Met) 
P Proline (Pro) 
G Glycine (Gly) 
  
polar hydrophylic  
S Serine (Ser) 
T Threonine (Thr) 
C Cysteine (Cys) 
N Asparagine (Asn) 
E Glutamic acid (Glu) 
  
negatively charged   
Q Glutamine (Gln) 
D Aspartic acid (Asp) 
  
positively charged  
K Lysine (Lys) 
R Arginine (Arg) 
H Histidine (His) 
  
aromatic   
F Phenylalanine (Phe) 
Y Tyrosine (Tyr) 
W Tryptophan (Trp) 
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5.4. Abbreviations  
% Percentage  
°C Degree Celsius 
µ Micro 
A Ampère 
ALL Acute Lymphoblastic Leukaemia 
AraC Cytarabine 
ASXL1 ASXL Transcriptional Regulator 1 
AZA Azacytidine  
bp  Basepair/basepairs  
BSA Bovine serum albumine 
cDNA Complementary DNA 
CML  Chronic Myeloid Leukaemia 
CN Cytogenetically normal 
CR Complete remission 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeat 
DAC Decitabine  
Del deletion 
Dest Distilled  
DMEM Dulbecco´s Modified Eagle Medium 
DMSO  Dimethyl Sulfoxide 
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferase  
DNMT3A DNA methyltransferase 3 alpha 
DNR Daunorubicin 
dNTP deoxynucleotide triphosphate 
dsDNA Double-stranded DNA  
DSMZ German Collection of Microorganisms and Cell Cultures 
DTT Dithiothreitol 
e.g. for example 
ECL  Enhanced chemoluminescence 
EDTA Ethylene diamine tetraacetic acid 
EED Embryonic Ectoderm Development Protein 
EGR1 Early growth response protein 1 
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ELN European LeukaemiaNet 
ESC Embryonic stem cell 
EZH2 Enhancer of zeste homolog 2 
FAB French-American-British classification system 
FACS Fluorescence activated cell sorter 
FBS Fetal bovine serum  
FLT3 Fms-like tyrosine kinase 3 
FOR Forward 
g Gram, genomic 
GFP  Green fluorescent protein 
GOF Gain of function  
h Hours  
H Histone, Histidine 
H3K27me1 Histone 3 lysine 27 mono-methylation 
H3K27me2 Histone 3 lysine 27 di-methylation 
H3K27me3 Histone 3 lysine 27 tri-methylation 
HBS  Hepes-buffered saline 
HMT Histone methyltransferase 
HOX  Homeobox 
HRP  Horseradish peroxidase 
HSC Haematopoietic stem cell  
i.v.  Intravenous 
IC50  Half-inhibitory concentration 
IL-3 Interleukin 3 
IL-6 Interleukin 6  
inv Inversion 
ITD Internal tandem duplication 
kb  Kilo base pairs 
Kd Knockdown  
kDa Kilodalton(s) 
Kg Kilogram 
KO Knockout  
l Liter  
LOF Loss of function  
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LSC Leukemic stem cell  
M Molar (mol/l) 
m Milli 
MDR Multidrug-resistance 
MDS Myelodysplastic syndrome  
min Minute(s) 
MLL Mixed Lineage Leukaemia 
MLPA  Multiplex Ligation-dependent Probe Amplification 
MPN Myeloproliverative neoplasm  
MRD Minimal residual disease 
mRNA  Messenger RNA 
Mut Mutated  
n.s. Not significant 
Nano Nano 
NGS Next-generation sequencing  
NMP1 Nucleophosmin-1 
OS Overall survival 
PAGE Polyacrylamide gel electrophoresis 
PB PiggyBac 
PBS  Phosphate buffered saline 
PCR Polymerase chain reaction 
PDX Patient-derived xenograft 
PMSF Phenylmethylsulfonyl fluoride 
PRC1 Polycomb repressive complex 1 
PRC2 Polycomb repressive complex 2 
RB/AP46 Histone-binding protein RBBP4  
REV Reverse 
RFS  Relapse free survival 
rh Recombinant human 
RNA Ribonucleic acid  
RNAi RNA interference 
rpm Rounds per minute 
RPMI Roswell Park Memorial Institute 
RT Room temperature, 
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SAH  S-adenosyl homocysteine 
SAM S-adenosyl-L-methionine 
sAML secondary AML 
SCF Stem cell factor 
SDS Sodium dodecyl sulfate 
sec Second 
SET Su(var)3-9, Enhancer-of-zeste and Trithorax 
sgRNA Single guide RNA  
S-HAM Sequential high dose AraC with mitoxantrone 
siRNA Small interfering RNA 
SNP Single nucleotide polymorphism 
t Translocation 
t-AML Therapy-related AML 
TBS Tris-buffered saline 
TET2 Tet methylcytosine dioxygenase 2 
Tm Primer Melting Temperature 
UPN Unique Patient Number 
V Volt  
VAF Variant allele frequency 
WB Western Blot 
WHO World Health Organization 
wt Wildtype  
α Alpha, Anti  
β Beta 
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